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Development of protein formulations in the solid and solution state involves 
stability studies during long-term storage (2-3 years). A long-term study of a protein 
under conditions leading to its rapid physical and chemical degradation often results 
in excessive use of resources and severe time constraints. To minimize these 
problems, a thorough preformulation study of protein behavior under different 
conditions is necessary.  An in depth understanding of the properties of proteins in 
both the solution and solid state may subsequently result in selection of conditions 
leading to adequate stability during storage. 
Preformulation studies of a protein in solution often involve a three step 
approach. In this method a protein is first characterized under a range of conditions 
(e.g. pH, temperature, etc.), and the data is then summarized in the form of an 
empirical phase diagram. This information is then used to design a high throughput 
screening approach to identify stabilizing compounds. This approach was employed 
for preformulation studies of vaccines against Clostridium difficile (C. difficile) -
associated disease. Such vaccines contain formaldehyde treated toxoids A and B in 
free or adjuvant bound form. Studies of C. difficile toxins and toxoids under a range 
of conditions revealed a stabilizing effect of formaldehyde crosslinking on the 
thermal stability of the toxoids. Furthermore, screening for stabilizing compounds 
resulted in the identification of conditions and specific compounds that lead to 




Preformulation studies of proteins in the solid state usually involve 
characterization of an amorphous solid in general (e.g. moisture content, crystallinity, 
structural relaxation, etc.) and specific protein properties (e.g. extent of protein 
structure preservation). Unfortunately, these characteristics of the solid and protein 
cannot usually predict protein stability during storage. Therefore, a more in depth 
understanding of amorphous matrices is needed. To understand the role of 
interactions between protein and expient as well as the homogeneity of 
protein/excipient mixtures, a study of a model system containing human Growth 
Hormone (hGH) and sugars (sucrose and trehalose) was performed. This study 
revealed that the extent of protein/excipient interaction can be used to describe the 
degree of homogeneity of a lyophilized mixture which can be related to the cryo- and 
lyo- protecting properties of the excipients. Additionally, it was seen that the rate of 
structural relaxation is proportional to the rate of insoluble aggregate formation.  
These studies of proteins in solution and the solid state allowed for the 
identification of conditions for long term stability studies of C. difficile vaccines and 
contributed to our understanding of the role of interactions between protein and 
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The role of biopharmaceuticals containing proteins and nucleic acids in the 
treatment of various chronic and severe diseases, as well as in preventing infectious 
diseases, is growing rapidly. Currently, over 350 biopharmaceuticals are in clinical 
trials.1   Unfortunately, biotechnology-based approaches suffer drawbacks due to the 
unique characteristics of biomolecules which lead to their decreased stability during 
storage.  For example, proteins usually have well defined secondary and tertiary 
structure, preservation of which is typically required for biological activity.  
Moreover, the loss of native characteristics, i.e. unfolding of proteins due to physical 
(e.g. aggregation) and chemical (e.g. deamidation, oxidation and isomerization) 
degradation during storage, can lead to immunogenicity and toxicity, as well as loss 
of potency.2-4  Thus, the development of biopharmaceuticals still remains a challenge 
and requires an in depth understanding of protein behavior in solution and solid states 
to achieve stable products. 
The studies described here are directed towards preformulation of a 
Clostridium difficile vaccine in solution state and an investigation of the role of 
protein-excipient interactions on the stability of lyophilized protein formulations. 
 2
1.2. Formulation of proteins 
 
1.2.1. Vaccine formulations 
 
Infectious diseases play a tremendous effect on survival of individuals, groups 
and nations throughout the human history. Increased human population and 
domestication of cattle led to adaptation of some of the animal pathogens to humans 
and ultimately increase of human pathogens. For example, the animal-originated 
pathogens include smallpox, influenza, tuberculosis, malaria, plague, measles and 
cholera. Human pathogens are divided into four classes which include bacteria, 
viruses, parasites and fungi. Among these pathogens viruses and bacteria are the most 
prominent as they lead to various diseases including cancer.5-9   
To prevent infectious diseases more than 70 vaccines have been developed. 
Most of these vaccines contain live attenuated organisms, inactivated / killed whole 
organisms, subunit conjugates and inactivated toxins (toxoids).6 Live attenuated 
vaccines (e. g. polio, yellow fever, measles, mumps, rubella, varicella, rotavirus, CA 
influenza, salmonella typhi, vibrio cholerae and adenovirus) are obtained by one of 
the four available approaches.5,10 These approaches involve usage of natural 
pathogens from another mammal, passage of wild-type viruses in tissue culture until 
virulence is greatly reduced, usage of mutants that are able to grow only at low 
temperatures (cold-adapted strains) and selective deletion or inactivation of genes in 
bacteria.5,10-14 Vaccines containing inactivated / killed whole organisms (e.g. polio, 
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rabies, Japanese encephalitis, hepatitis A and bacilus antracis) are obtained by 
inactivation of organisms which leads to their death and loss of infectivity. Subunit 
and conjugate vaccines (hepatitis B, salmonella typhi) contain polysaccharides, 
proteins or polysaccharide/protein conjugates which represent epitopes on the 
organism’s surface.5,15-17
Many pathogenic bacteria produce toxins that are responsible for various 
diseases such as botulism, diphtheria and etc. There are two types of bacterial toxins: 
the lipopolysaccharides (endotoxins) and proteins (exotoxins). Lipopolysaccharides 
are usually associated with bacterial cell walls, whereas proteins are often released 
from bacteria during their exponential growth. The exotoxins may act at sites 
removed from the site of bacterial growth.  Some exotoxins (tetanus, shigella 
neurotoxin and diphtheria) are considered to be very powerful and potent human 
poisons that can lead to lethality comparable to snake venom.18
Treatment of the toxins with formaldehyde leads to reaction with the N-
terminal amino acid residues and the side chains of arginine, cysteine, histidine and 
lysine residues, and the subsequent formation of methylol groups and Schiff-bases as 
well as intramolecular methylene bridges with amine, phenol, imidazole or indole 
groups.19-25 The reaction of formaldehyde with primary amine-containing side chains 
is represented in Scheme 1. The intramolecular crosslinking of toxins with 
formaldehyde leads to their complete inactivation with at least partial retention of 
their immunogenicity. In addition, the crosslinking may result in changes in the 
toxin’s shape and overall stabilization of their structure.26-29  
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 Live vaccines are usually very effective, however, they carry a risk of 
reverting to virulent forms and subsequent disease in patients. On the other hand, 
killed organisms and toxoids are safer, but they typically produce weaker immune 
responses and require multiple doses.5-11 The immunogenicity of vaccines is usually 
increased by introducing adjuvants to the formulation. Adjuvants, typically 
aluminum-containing salts, tend to adsorb antigens and lead to higher immune 
responses through a variety of still poorly understood mechanisms.30-33  
To be effective as vaccines, antigens must be stable during storage. Most 
vaccine instability and failure to initiate immune responses originates from physical 
and chemical degradation.34-38 Thus, studies directed towards characterization of 
antigens under different conditions and screening for stabilizing compounds is of a 
great importance and in many cases is a central key to the development of an 
effective vaccine. 
A systematic approach to preformulation development has been initiated in 
our group. The approach consists of the following consecutive steps: biophysical 
characterization of protein/virus under different conditions (e.g. pH, temperature, 
concentration, ionic strength and etc), visualization of the data in the form of an 
empirical phase diagram and screening for stabilizing compounds. Identification of 
the condition(s) leading to natively-folded protein as well as stabilizing compound(s) 
allows rapid selection of formulation(s) for accelerated and long-term stability 
studies. This approach has been applied in several protein and viral systems and has 
been shown to be very effective.35,39-48  
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The approach described above was utilized for preformulation studies of a 
proposed Clostridium difficile (C. difficile) vaccines. C. difficile vaccines contain 
toxoids A and B, which are derived from corresponding toxins by crosslinking with 
formaldehyde. 
C. difficile  is a gram-positive, endospore forming, rod-shaped bacterium 
(Figure 1).18 C. difficile has more than 150 ribotypes, 24 toxinotypes and produces 
two large toxins designated A (308 kDa, 2,710 amino acids) and B (260 kDa, 2,366 
amino acids). The toxins are responsible for C. difficile-associated disease (CDAD), 
which manifests itself as nosocomial diarrhea and pseudomembranous colitis.49-53  
Emerging strains of C. difficile lead to severe CDAD outbreaks in North America and 
Europe and therefore require preventive vaccination.51
C. difficile toxins A and B exhibit 49% amino acid identity and belong to the 
large clostrodial cytotoxin (LCT) family, which includes the Clostridium sordelii 
toxins and Clostridium novyi alpha toxin. Toxins A and B possess high molecular 
weight, an N-terminal enzymatic domain (e.g. residues 1-543), a central hydrophobic 
region (e.g. residues 900-1,200) and a C-terminal domain carrying carbohydrate 
recognition sequence repeats (e.g. residues 1,750-2,710 or 2,366).51,54-58 A schematic 
representation of toxins’ structure is illustrated in Figure 2 (adapted from reference 
58).  It is thought that the C-terminal part binds to cell surface carbohydrate 
containing receptors which leads to endocytosis of the toxin.59,60 The central 
hydrophobic region then undergoes pH-induced conformational changes, which 
mediate formation of pores and translocation of the amino-terminal fragment from 
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early endosomes to the cytoplasm.61-63 In the cytosol, the N-terminal enzymatic 
fragment catalyzes glycosylation of Rho/Ras proteins at Thr37/35, which leads to 
shutdown of essential cellular processes.59,64  The proposed mechanism of toxins’ 
action is represented in Figure 3 (please note that the model was adapted from 
reference 63). The structure of the N-terminal domain of toxin B (Figure 4, adapted 
from reference 64) and the C-terminus domain of toxin A (Figure 5, adapted from 
reference 59) are well characterized although the complete structure of the toxins is 
not yet available. The role of the hydrophobic region is especially poorly 
understood.64 The N-terminal catalytic portion of toxin B consists of 543 residues, 
which are arranged in a mixed α/ß-structure of 11 ß-strands in the core and 21 α-
helices on the periphery.65 The 39 repeats in the C-terminal domain (960 residues) 
from toxin A are arranged in the form of a ß-selenoid fold.60 The toxins possess 
differences in structure as well as in degree of the enzymatic activity. The cell-surface 
carbohydrate receptor binding C-terminal domain in toxin A contains 39 repeats (861 
residues) whereas toxin B has 19 repeats (515 residues). It was observed that only 
toxin A is capable of entering into enterocytes in animals while both toxins are 
enterotoxic in humans. In addition, the enzymatic activity of toxin B is approximately 
100-fold greater than that for toxin A.58  
Unfortunately, treatment of CDAD with antimicrobial agents (metrnidazole 
and vancomycin) leads to recurrence of the disease.66-68 To induce immunity against 
CDAD a vaccination employing the administration of formaldehyde crosslinked 
(inactivated) toxoids A and B is envisioned, and the formulation of a stable vaccine is 
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required.69,70,71-74 The preformulation studies of C. difficile toxins and toxoids 
conducted in our study can potentially assist in the development of a commercial 
vaccine. 
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1.2.2. Solid protein formulations 
 
To achieve stability of biopharmaceuticals in solution, various additives ( i.e. 
excipients) have been employed.  It has been found that in solution, excipients can 
stabilize the native structure of proteins by preferential exclusion. The preferential 
hydration of a protein in presence of certain compounds increases the chemical 
potential of the system and forces the protein to attain compactly folded state(s).75,76   
Simple empirical testing of well established stabilizers is often, however, not 
adequate. For many proteins, it remains a challenge to find appropriate conditions for 
stabilization and improvement of a shelf life. To overcome these difficulties, 
lyophilization (freeze-drying) and spray-drying methods have provided alternatives to 
solution stabilized proteins.  An optimal shelf life of 18-24 months can often be 
achieved by these methods.  To protect proteins during the process of lyophilization 
(freezing, primary and secondary drying) and spray-drying, a variety of different 
excipients have been employed.77,78   
There are two main proposed mechanisms, which attempt to explain the 
protection of proteins by certain compounds during lyophilization and subsequent 
storage. According to the “vitrification” (kinetic) theory, excipients form rigid glassy 
matrices, which slow down internal macromolecular motions thus providing reduced 
chemical reactivity and physical changes.79 The “water substitution” 
(thermodynamic) hypothesis suggests that the excipients replace water during drying 
by hydrogen bonding to the protein, which leads to the stabilization of protein 
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secondary structure.80 Numerous empirical observations have shown that neither of 
the above theories can explain the behavior of protein in solid formulation by 
themselves. Although degradation of a protein in lyophilized formulation (containing 
excipients) is significantly decreased compared to solution formulation, the protein in 
a lyophilized state still has a tendency to degrade physically (e.g. aggregation, 
unfolding) and chemically (e.g. deamidation, oxidation) during long term 
storage.77,78,81-83   
 To better understand the characteristics of lyophilized formulation that 
influence stability of a protein, amorphous matrices are studied in a great detail. 
Amorphous matrices (glasses) are very complex in nature as they possess 
characteristics of a solid and a liquid at the same time. Amorphous solids are 
unordered like liquids and have high viscosity like solids.84 Amorphous solids are 
metastable (possess high free energy) and therefore have increased molecular 
mobility of the matrix compared to crystals.  The high mobility (structural relaxation) 
of matrix is related to its tendency to attain more compact state with lower free 
energy over the storage (annealing).85,86 Molecular mobility of components in 
amorphous matrix can be described by long range (translation and rotation) and short 
range (vibration) motions. The long range movements are called α-motions whereas 
short range movements are often referred as ß-motions.87 Additionally, proteins in 
solution and solid state demonstrate numerous molecular motions by themselves. The 
motions can be categorized as small-scale molecular vibrations, local rotations of 
individual side chains and large scale motions of entire protein.88-91 The mixture 
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containing protein and excipient represents “molecular dispersion” or “solid 
solution”.92 Complex interplay between the properties of amorphous matrix such as 
mobility of components in a mixture, local motions of protein alone and stability of 
protein during storage is still unclear and remains under investigation.93-95
  The indirect assessment of strength of an amorphous matrix can be 
performed with differential scanning calorimetry (DSC) which measures temperature 
at which rigid “glassy” state of an amorphous solid transforms into flexible “rubbery” 
state. This temperature is called a glass transition temperature (Tg) and is usually 
related to stability of the protein in amorphous matrix. It is believed that if protein 
formulation is stored at temperature which is 50°C below the Tg, then the formulation 
will have higher stability during storage. This estimation of optimum storage 
temperature by this approach is often accurate, however, it can not allow prediction of 
protein stability during storage at different temperatures.96 Alternatively, indirect 
measurements of structural relaxation times of an amorphous matrix can be 
performed by variety of techniques such as DSC, dielectric relaxation spectroscopy 
(DRS), thermostimulated current (TSC), isothermal microcalorimetry, 
thermomechanical analysis (TMA), neutron scattering and solid state NMR.80 
Estimated, employing DSC and TAM measurements, time of structural relaxation at 
different temperatures has shown to be useful in prediction of protein stability at 
different temperatures for some proteins.81 However, the predicted with DSC and 
TAM measurements structural relaxation time describes mostly α-motions and may 
not always be related to protein stability during storage.97 An attempt to relate ß-
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motions that are measured by employing neutron scattering has shown to be effective 
in predicting preservation of protein activity during storage.87,98 On the other hand, 
for some protein formulations a preservation of protein native structure in solid state 
is a better parameter for describing protein stability during storage.97,99  
 It was hypothesized that interactions between protein and excipient play an 
important role not only in protection of protein from lyophilization induced stresses 
(e.g. cold induced and drying induced denaturation) but also play a significant role in 
stabilization of protein during storage.80 The protein/excipient interactions can be 
measured with variety of techniques such as isoperibol solution calorimetry (ISC), 
water sorption analysis (WSA), differential scanning calorimetry (DSC) and Fourier 
transform infrared spectroscopy (FTIR).92,96,100-104 Recent studies of lyophilized 
protein formulations have demonstrated that excipients that are able to more 
extensively hydrogen bond (H-bond) with proteins do, in fact, enhance protein 
stability.100 Excipients usually H-bond to proteins during secondary drying which 
leads to the preservation of protein structure through favorable solute/protein surface 
interactions. This, in turn, leads to enhanced stability during long term storage.105  
Although studies have shown that some H-bonding excipients (e.g. sucrose) produce 
better protein stability than others (e.g. trehalose),106   there has been no systematic 
study of any protein that establishes a direct relationship between the magnitude of 
such protein-excipient interactions (e.g. homogeneity of mixture) and the stability of 
proteins.  
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 Understanding of such relationships that are characteristic of amorphous 
matrices and the stability of proteins in solid formulations are the primary focus of a 
major aspect of this work.  
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1.3. Specific aims and chapters summaries 
 
1.3.1. Physical characterization of Clostridium difficile toxins and toxoids - effect of 
formaldehyde crosslinking on thermal stability 
 
The specific aims of Chapter 2 involve the biophysical characterization of C. 
difficile toxins and toxoids and investigation of the effect of formaldehyde 
crosslinking on toxoids’ thermal stability.   
 
Nosocomial diarrhea and pseudomembranous colitis causing toxins A and B 
from Clostridium difficile were studied at pH 5-8 and over the temperature range of 
10-85°C. The proteins were crosslinked with formaldehyde to inactivate them to 
toxoid forms and permit their use as vaccines. Structural changes and aggregation 
behavior were monitored using circular dichroism, intrinsic and extrinsic (ANS) 
fluorescence spectroscopy, turbidity measurements, high resolution UV absorbance 
spectroscopy and dynamic light scattering. The combined results were then 
summarized in empirical phase diagrams. Toxins A and B had similar secondary 
structure with a combination of helical, ß-sheet and unordered character and were 
partially unfolded at pH 5-5.5. Upon heating, toxin A at all pH values partially 
unfolded at ~45°C and formed insoluble aggregates at ~50°C. Toxin B partially 
unfolded at ~40°C, and upon heating to ~50°C precipitated at pH 5.0-6.0 and formed 
soluble aggregates at pH 6.5-7.5. The thermal stability of the toxins was pH 
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dependent with the proteins more thermally stable at higher pH. Similar studies of 
formaldehyde crosslinked toxoids A and B revealed enhanced thermal stability, in 
which secondary and tertiary structure changes, as well aggregation, were delayed by 
about 10°C. These studies reveal both similarities and differences between C.  
difficile toxins A and B and demonstrate the stabilizing effect of formaldehyde 
crosslinking on the thermal stability of their corresponding toxoids.   
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1.3.2. Preformulation studies of Clostridium difficile toxoids A and B 
 
The specific aim of Chapter 3 is directed toward identification of stabilizing 
compound(s) of free and adjuvant bound C. difficile toxoids.   
 
To enhance the physical stability of Clostridium difficile toxoids A and B, 
screening for stabilizing compounds was performed. The screening of 30 GRAS 
compounds at various concentrations and in several combinations was performed in 
two parts. First, a high-throughput aggregation assay was used to screen for 
compounds that delayed or prevented aggregation of toxoids under stress conditions 
(toxoids at pH 5-5.5 were incubated at 55°C for 55 or 75 min). Compounds which 
stabilized both proteins were further studied for their ability to delay unfolding under 
conditions leading to a presumably native-like folded state (pH 6.5). The thermal 
stability of the toxoids on the surface of Alhydrogel® was monitored with DSC and 
also showed significant improvement in the presence of certain excipients. In 
conclusion, this study has generated information concerning the free and adjuvant 
bound toxoids behavior under a range of conditions (temperature, solutes) that can be 
used to design pharmaceutical formulations of enhanced physical stability.  
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1.3.3. Stability of Growth Hormone in lyophilized formulations - effect of protein-
excipient interactions and molecular mobility 
 
The specific aim of Chapter 4 is to understand the relationship between the 
extent of protein-excipient interactions, structural relaxation of amorphous matrix and 
physico-chemical stability of a protein.  
 
For this human Growth Hormone (hGH) was lyophilized with sucrose and 
trehalose in a 1:2 weight ratio. Potential protein-excipient interactions were analyzed 
immediately after lyophilization with Isoperibol Solution Calorimetry, Water 
Sorption Analysis, Differential Scanning Calorimetry (DSC) and FTIR. Fragility of 
the amorphous matrix was determined from the dependence of the glass transition 
temperature on scanning rate (with DSC). The initial relaxation time of the 
amorphous formulations was calculated by the Vogel–Tammann–Fulcher (VTF) 
equation. The physical and chemical stability of the hGH during storage at 50°C was 
monitored by RP-HPLC, SEC-HPLC and UV absorbance. The hGH formulations 
containing sucrose demonstrated greater protein-excipient interactions and faster 
initial relaxation time compared to trehalose formulations. Although both 
formulations had similar chemical stability (deamidation), their physical stabilities 
(aggregation) were different. The hGH/sucrose formulation showed a higher rate and 
lower extent of the formation of insoluble aggregates. The decreased amount of high 
order aggregates in the sucrose formulations could be correlated with the greater 
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extent of protein-excipient interaction.  In contrast, the higher rate of aggregation seen 
in the sucrose formulations could be correlated with the higher molecular mobility of 
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Figure 1.2. Structure of C. difficile toxins A and B. Toxins A and B consist of three 
major domains: N-terminus (responsible for enzymatic activity), C-terminus 
(involved in receptor binding) and middle part (potentially involved in the 
































igure 1.3. Model of the uptake of C. difficile toxins. The uptake of the toxins 
volves binding to receptors on the surface of target cells, subsequent endocytocis, 
leavage of N-terminal catalytic domain with subsequent  translocation from an 
cidic endosomal compartment into the cytosol. In the cytosol, the toxins glucosylate 





































Figure 1.4. Stereoview of the N-terminal catalytic portion of toxin B. Structure is 








































Figure 1.5. Stereoview of solenoid structure of C-therminal domain of toxin A. (A) 












































Scheme 1.1. Crosslinking of side chains containing primary amines with 
 
 















Physical Characterization of Clostridium difficile Toxins and 
Toxoids - Effect of the Formaldehyde Crosslinking on Thermal 
 40
2.1. Introduction 
Clostridium difficile (C. difficile) is a gram-positive, endospore forming rod-
aped bacterium.1 C. difficile has more than 150 ribotypes, 24 toxinotypes and 
roduces two large toxins designated A (308 kDa, 2,710 amino acids) and B (260 
Da, 2,366 amino acids). The toxins are responsible for C. difficile-associated disease 
(CDAD), which manifests itself a diarrhea and pseudomembranous 
colitis.2-6  Unfortunately, treatment of CDAD with antimicrobial agents 
(metronidazole and vancomycin) leads to recurrence of the disease.7-9 To induce 
immunity against CDAD both passive and active vaccination have been attempted, 
with the active vaccination being more effective.   Vaccination employing the 
adm en 
shown to be effective in hamster ults and patients with recurrent 
CDAD.12-15  
C. difficile toxins A and B exhibit 49% amino acid identity and belong to the 
large clostrodial cytotoxin (LCT) family, which includes the Clostridium sordelii 
toxins and Clostridium novyi alpha toxin. Toxins A and B possess high molecular 
weight, an amino-terminal enzymatic domain (e.g. residues 1-543), a central 
hydrophobic region (e.g. residues 900-1,200) and a carboxy-terminal domain carrying 
carbohydrate recognition sequence repeats (e.g. residues 1,750-2,710 or 2,366).4,16-20 
It is thought that the carboxy-terminal part binds to cell surface carbohydrate 
containing receptors which leads to endocytosis of the toxin.21,22 The central 






inistration of formaldehyde crosslinked (inactivated) toxoids A and B, has be
s, healthy ad
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mediate formation of pores and translocation of the amino-terminal fragment from 
early e
o acid residues and the side chains of arginine, cysteine, histidine and 
lysine r
ndosomes to the cytoplasm.23-25 In the cytosol, the amino-terminal enzymatic 
fragment catalyzes glycosylation of Rho/Ras proteins at Thr37/35 which leads to 
shutdown of essential cellular processes.26 The structure of the amino-terminal 
domain of toxin B and the carboxy-terminus domain of toxin A are well characterized 
although the complete structure of the toxins is not yet available. The role of the 
hydrophobic region is especially poorly understood.27 To explore the structural 
characteristics of both toxins under a range of conditions, this study elucidates the 
tertiary and secondary structure as well as aggregation behavior at pH 5.5-8.0 for 
toxin A and pH 5.0-7.5 for toxin B. In addition, the properties of the toxins were 
monitored as a function of temperature over the same pH interval. 
Treatment of the toxins with formaldehyde leads to reaction with the N-
terminal amin
esidues, and the subsequent formation of methylol groups and Schiff-bases as 
well as intramolecular methylene bridges with amine, phenol, imidazole or indole 
groups.28-34 The intramolecular crosslinking of toxins with formaldehyde leads to 
their complete inactivation with at least partial retention of their immunogenicity. In 
addition, the crosslinking may result in changes in the toxin’s shape and overall 
stabilization of structure.35-38
Since the formaldehyde crosslinked C. difficile toxoids A and B are candidates 
for vaccine development, a better understanding of their structures as a function of pH 
and temperature is of a great interest for the design of stable vaccine formulations.  A 
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comparison of the toxins’ and toxoids’ behaviors was also performed to probe the 
effect of formaldehyde crosslinking on their structures and thermal stabilities, to 
further facilitate their use as vaccine agents.  
 
2.2. Experimental methods 
2.2.1. Materials 
Toxins and toxoids A and B were produced in highly purified form by Acambis Inc. 
(Cambridge, MA). The production and purification of the material is described 
elsewhere.15 The concentration of the proteins was determined by UV absorbance at 
280 nm using extinction coefficients of 1.173 for toxin/toxoid A and 0.967 for 
toxin/toxoid B. All reagents used in these studies were of analytical grade and were 
purchas
ysical stability  
 
ed from Sigma (St. Louis, MO).  MOPS/succinate (10 mM of each) buffers 
(pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0) containing 100 mM NaCl were used for 
characterization of the proteins over the entire pH range examined. Sodium phosphate 
buffer (5 mM) at pH 7.0 was used for assignment of secondary structure by CD. For 
buffer exchange, protein was dialyzed at refrigerator temperature using Slide-A-
Lyzer® Dialysis Cassettes, 10 kDa MWCO (Pierce, Rockford, IL).  
 
2.2.2. Characterization of ph
2.2.2.1. Sample preparation. 
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 Protein solutions were studied at a concentration of 0.2 mg/ml for CD studies and 0.1 
mg/ml for fluorescence and UV absorption analyses. No concentration dependence 
was seen over this concentration range. Toxin/toxoid A was studied at six pH values 
from 5.5 to 8.0 at half unit pH intervals. Toxin/toxoid B was studied at six pH values 
it pH intervals. The pH range selected was chosen to be 
ical isoelectric point for each toxin (5.50 for toxin A and 4.42 for 
). Details of this 
rocedure are described elsewhere.39,40 Spectral analysis was performed using 
nd derivative spectra were obtained by 
sing a nine point filter and the Savitsky-Golay method to fit data to a third order 
e smoothed using 99 interpolated points between each 
raw data point, permitting 0.01 nm resolution.  Peak positions were determined from 
from 5.0 to 7.5 also at half un
above the theoret
toxin B).  Each sample was evaluated in duplicate to ensure reproducibility of the 
measurements.  
 
2.2.2.2. High-Resolution UV Absorbance Spectroscopy.  
High-resolution UV absorbance spectra were acquired using an Agilent 8453 UV-
visible spectrophotometer. The spectra were obtained every 2.5°C over the 
temperature range of 10 to 85°C with a 5 min incubation (sufficient for equilibrium to 
be reached) at each temperature. Aggregation of the proteins was studied by 
simultaneously monitoring optical density at 350 nm (OD 350 nm) as a function of 
temperature. Second derivatives of UV absorbance spectra in the near-UV region 
were used for construction of an initial empirical phase diagram (EPD
p
ChemstationTM software from Agilent.  Seco
u
polynomial.  The spectra wer
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the interpolated spectra using Microcal OriginTM 6.0 software.  This EPD is a 
measure of protein tertiary structure at each temperature/pH condition (construction 
of the EPD is discussed below).  
 
2.2.2.3. Far-UV Circular Dichroism (CD) Spectroscopy.  
CD spectra were acquired using a Jasco J-810 spectropolarimeter equipped with a 6-
position Peltier temperature controller. CD spectra were obtained from 260-190 nm 
with a scanning speed of 20 nm/min, a 2 sec response time and an accumulation of 2. 
ssignment of secondary structure was performed with DICHROWEB software 
n residue weight of 114 was 
A
utilizing the CDSSTR (7) analysis algorithm.41,42 A mea
used for toxin/toxoid A and 110 for toxin/toxoid B. To study thermal transitions 
(melting curves) of the proteins (in sealed cuvettes with a 0.1-cm pathlength), the CD 
signal at 208 nm was monitored every 0.5°C over the 10 to 85°C temperature range 
employing a temperature ramp of 15°C/hr. The CD signal was converted to molar 
elipticity by Jasco Spectral Manager software. The midpoint temperature of the 
thermal transition was obtained from a sigmoid fitting of the melting curves using 
Origin software. 
 
2.2.2.4. Intrinsic Tryptophan (Trp) Fluorescence Spectroscopy. 
 Fluorescence spectra were acquired using a Photon Technology International (PTI) 
spectrofluorometer (Lawrenceville, NJ) equipped with a turreted 4-position Peltier-
controlled cell holder. An excitation wavelength of 295 nm was used to excite Trp 
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and the emission spectra (>95% Trp emission) were collected from 305 to 450 nm 
with a step size of 0.5 nm and 0.5 sec integration time. Excitation and emission slits 
of 4 nm and a 1-cm pathlength quartz cuvette were used. Emission spectra were 
ollected every 2.5°C with 5 min of equilibration over a temperature range of 10 to 
 emission spectrum. Peak 
ectra were obtained from polynomial fits using Origin software. 
c
85°C. A buffer baseline was subtracted from each raw
positions of the emission spectra were obtained from polynomial fits using Origin 
software. 
 
2.2.2.5. ANS Fluorescence Spectroscopy.  
Accessibility of apolar sites on the proteins was monitored by fluorescence emission 
of the extrinsic probe 8-Anilino-1-naphthalene sulfonate (ANS). Each sample 
contained a 20-fold molar excess of ANS to protein. The ANS was excited at 372 nm 
and emission spectra were collected from 400 to 600 nm with a step size of 2 nm and 
a 1-sec integration time. Emission spectra were collected every 2.5°C with 5 min of 
equilibration over a temperature range of 10 to 85°C. The ANS-buffer baseline at 
each corresponding pH was subtracted from the raw emission spectra. Peak positions 
of the emission sp
 
2.2.2.6. Dynamic Light Scattering.  
The mean hydrodynamic diameter of the proteins at pH 6.5 was analyzed using a 
dynamic light scattering instrument (Brookhaven Instrument Corp., Holtzille, NY) 
equipped with a 50 mW diode-pumped laser (λ = 532 nm). The scattered light was 
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monitored at 90° to the incident beam, and autocorrelation functions were generated 
using a digital auto-correlator (BI-9000AT). The hydrodynamic diameter was 
calculated from the diffusion coefficient by the Stokes-Einstein equation using the 
method of cumulants (lognormal number based). In addition, the data was fit to a 
non-negatively constrained least squares algorithm to yield multi-modal distributions 
(MSD). The instrument was equipped with a temperature-controlled circulating water 
bath RTE111 (Neslab, Newington, NH) and the hydrodynamic diameter was 
onitored over a temperature range of 10 to 85°C. 
x n 
ensity matrices, where n is the number of variables (e.g. CD, fluorescence, OD 350 
ombination. The density matrices were used to 
m
 
2.2.2.7. Empirical Phase Diagrams (EPDs).  
Empirical phase diagrams were constructed as described previously.40 CD molar 
elipticity at 208 nm, intrinsic Trp fluorescence intensity, ANS fluorescence intensity 
and optical density at 350 nm data sets were used for construction of each phase 
diagram. Near-UV second derivatives peak positions were also used for construction 
of separate EPDs to visualize changes in aromatic residue environments.  All 
calculations were performed using Matlab software (The MathWorks, Natick, MA). 
Briefly, the experimental data sets were represented as n-dimensional vectors in n 
d
nm, etc) at each pH-temperature c
derive n sets of eigenvalues and eigenvectors. The three eigenvectors which 
correspond to the highest eigenvalues were employed to re-expand the data into three 
dimensions, and each vector was assigned a color (red, green or blue). The resulting 
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multi-colored plots represent contributions of each vector at a given pH/temperature 
point. The regions of the EPDs with similar color indicate similar physical states of 
the protein. A detailed explanation of the calculations involved in construction of 
EPDs is presented elsewhere.40
 
2.3. Results  
 
2.3.1. High-Resolution UV Absorbance Spectroscopy 
Second derivative UV spectra of the toxins and toxoids revealed the presence 
ks are approximately positioned at the of six negative peaks (Figure 2.1). The pea
following wavelengths: 253 nm (Phe), 260 nm (Phe), 266 nm (Phe/Tyr), 277 nm 
(Tyr), 285 nm (Tyr/Trp) and 292 nm (Trp) at 10°C.40 Changes in the position of 5 of 
the peaks are shown over the indicated temperature range for toxin/toxoid A (Figure 
2.2) and toxin/toxoid B (Figure 2.3.).  
In the case of toxin A, the peak positions first shifted to lower wavelength 
(blue shift) by 1-25 nm and then to higher wavelength (red shift) upon heating (Figure 
2.2a). The onset and magnitude of the shifts were earlier and higher for protein at 
lower pH values. Blue shifts are generally indicative of changes in aromatic side 
chain environments towards more polar conditions and are consistent with unfolding 
of the protein. In contrast, red shifts are generally associated with more apolar 
environments and typically result from the formation of aggregated protein upon 
heating. Thus the observed shifts of the peak positions at about 45°C suggest that 
 48
toxin A undergoes partial unfolding with subsequent protein association and 
ultimately precipitation. In the case of toxoid A, the peak positions were red shifted 
by 1-6 nm upon heating to ~50°C, where the onset and magnitude of the shift was 
earlier and higher for protein at lower pH (Figure 2.2b). The red shift of the peak 
ositions is consistent with formation of visually observed insoluble aggregates at 
atures and increased variability of the data. The absence of unfolding 
lue shift) prior to precipitation and delayed onset of the thermal transition in toxoid 
o tertiary structure with more 
pronou





A suggests that the formaldehyde crosslinking leads t
nced thermal stability.  
For toxin B, the peak positions shifted by 1-6 nm and the direction of the 
shifts was pH sensitive (Figure 2.3a). Toxin B at pH 5.0 and 5.5 demonstrated 
significant blue shifts in the peak positions at about 45°C, whereas at higher pH the 
peaks were slightly red shifted upon heating.  The blue shifts in the peak positions at 
low pH are indicative of thermally in
d precipitation. The small shifts in peak position at higher pH suggest little or 
no change in the environment of the aromatic residues upon heating. The peak 
positions of toxoid B were red shifted by 0.1-1 nm upon heating to about 50°C 
(Figure 2.3b). The observed precipitation of toxoid B at pH 5.0 and 5.5 at elevated 
temperatures did not lead to significant shifts of the peak positions. These 
observations again suggest that the formaldehyde crosslinking of toxin B leads to 
tertiary structure with increased thermal stability.  
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The aromatic residue’s peak positions as a function of pH and temperature are 
summarized in the form of empirical phase diagrams for toxins/toxoids A and B in 
Figure 4. In this case, the data for the corresponding toxin and toxoid was processed 
together as a single matrix permitting a direct comparison between the two proteins. 
The EPDs clearly show more pronounced changes in tertiary structure of toxin A 
compared to toxin B, and of toxins in general compared to their corresponding 
toxoids. In the cases of toxin A and toxin B (only at pH 5.0 and 5.5), the appearance 
of regions with clearly different color at elevated temperature indicates more dramatic 
changes in the aromatic residue’s environment. The change in color at about 50°C 
seen fo
 and 5.5 indicates the presence of 
soluble aggregates (Figure 2.5c). Toxin B formed insoluble aggregates at ~ 45°C at 
r all proteins suggests a change in the proteins tertiary structure and correlates 
well with the actual observed changes in peak positions.  
The tendency of the proteins to aggregate at elevated temperature was directly 
monitored employing the optical density at 350 nm (OD 350 nm) and is summarized 
in Figure 2.5. The turbidity of toxin/toxoid A increased at all pH values upon heating. 
The observed decrease of the OD 350 nm correlates directly with protein precipitation 
and adsorption to the walls of the cuvvette.  Both toxin A and toxoid A displayed an 
increasing onset temperature of aggregation with increasing pH (Figure 2.5e). Toxoid 
A started to precipitate at higher temperature compared to its crosslinked homologue 
(Figure 2.5b). In addition, toxoid A had a greater pH sensitivity to aggregation with 
small changes in pH producing a significant delay in the onset of precipitation.  





, ~ 70°C at pH 5.5 and ~ 75°C at pH 6.0. The temperature effect on the OD 
350 nm was small at pH 6.5-7.5. The increased turbidity of toxoid B at pH 5.0 
indicates the presence of soluble aggregates which started to precipitate at ~ 55°C 
(Figure 2.5d).  Toxoid B at pH 5.5 formed insoluble aggregates at ~ 65°C. Toxoid B 
at pH 6.0-7.5 demonstrated only a small effect of temperature on OD 350 nm. Toxoid 
B at pH 6.0 did not appear to form insoluble aggregates. The onset of the toxoid’s 
aggregation was delayed by ~10°C compared to the toxins. These observations once 
again support the greater stability of the toxoids against aggregation at elevated 
temperatures.   
 
2.3.2. Far-UV Circular Dichroism (CD) Spectroscopy 
The CD spectra of the toxins and toxoids at 10°C displayed double minima at 
approximately 208 and 222 nm (Figure 2.6). The spectra of the proteins in the 
absence of sodium chloride (which interferes with data collected in the far UV) 
showed a good fit to algorithm reconstructed data (DICHROWEB) and allowed us to 
estimate a secondary structure of ~35% α-helix, ~20% ß-sheet, ~ 20% turns and 
~25% unordered regions for toxins/toxoids A and B (Table 2.1). Toxin/toxoid A at 
pH 5.5 and toxin B at pH 5.0 and 5.5 display lower molar ellipticity suggesting less 
ordered structure (Figure 2.6).  
Changes in the CD signal at 208 nm upon heating were monitored for
nd toxoids (Figure 2.7). The CD signal at 208 nm decreased significantly for 
toxin and toxoid A indicating at least partial unfolding and perhaps protein 
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aggregation at higher temperature (Figure 2.7a,b). The midpoint of the thermal 
transitions (Tm) was pH dependent and occured at lower temperature for protein at 
low pH (Figure 2.7e).  The Tm of toxoid A was increased by about 6°C at pH 5.5 and 
about 12°C at pH 8.0 compared to toxin A.  
Toxin B displayed considerable precipitation at pH 5.0-6.0 upon heating and 
therefore produced a significant decrease of the signal at 208 nm (Figure 2.7c). This 
precipitation was preceded by a slight decrease of the signal at ~ 25°C at pH 5.0, 
~30°C at pH 5.5 and ~ 35°C at pH 6.0. Heating of toxin B at pH 6.5-7.5 led to small 
changes in secondary structure corresponding to subtle thermally induced 
conform tional changes in the protein at ~ 43°C at pH 6.5, ~ 45°C at pH 7.0 and  ~ 
icant decrease of the signal at 
208 nm
er the pH range examined (data not shown). Spectral 
change
a
47°C at pH 7.5. Toxoid B at pH 5.0 and 5.5 had a signif
 due to thermally induced precipitation (Figure 2.7d). At pH 5.5 toxoid B 
showed a biphasic thermal transition presumably reflecting a secondary structure 
decrease at ~45°C and precipitation at ~65°C. Heating of toxoid B at pH 6.0-7.5 led 
to smaller changes in secondary structure. The anticipated increase in Tm with 
increased pH was seen here as well (Figure 2.7e).  Reversibility of the toxin/toxoid B 
CD spectral changes at pH 6.5-7.5 was studied upon cooling the previously heated 
samples to 10°C. The structural changes were not reversible, however, the changes of 
the CD spectra were similar ov
s for protein at pH 7.0 are illustrated in Figure 8. The secondary structure 
assignment of the previously heated protein (in buffer without NaCl) is summarized 
in Table 2.1.  Toxin/toxoid B had increased ß-sheet and unordered character upon 
 52
heating which suggests that the heating induced partial unfolding leads to structural 
reorganization and possibly formation of soluble aggregates (supported by OD 350 
nm data). The Tm of toxoid B was delayed by about 22°C at pH 5.0 and by about 
14°C at pH 7.5 compared to unmodified toxin B. The toxins and toxoids had similar 
shapes to their thermal transitions although the toxoids had transitions at higher 
temperatures.  
 
2.3.3. Intrinsic Trp Fluorescence Spectroscopy  
  The tertiary structure of the proteins as a function of temperature was also 
studied by measuring the intensity and peak position of their Trp emission (Figure 
2.9). There are 25 Trp residues in toxin A and 16 in toxin B. Monitoring of Trp 
emission at elevated temperature was not possible for toxin/toxoid A at all pH values 
and toxin/toxoid B at pH 5.0-5.5 due to broadening of the emission peak by excessive 
light scattering caused by aggregating protein. The onset of emission peak broadening 
in toxin A occurred at ~ 47.5°C at pH 5.0-6.5 and ~ 50°C at pH 7.0-8.0 (Figure 2.9 
a,e). The onset of emission peak broadening in toxoid A was pH dependent and 
occurred at ~ 47.5°C at pH 5.5, ~ 50°C at pH 6.0,  ~ 53°C at pH 6.5, ~ 53°C at pH 
7.0, ~ 55°C at pH 7.5 and  ~60°C at pH 8.0 (Figure 2.9 b,f). Toxin and toxoid B 
displayed an onset of emission peak broadening at ~40°C at pH 5.0 and ~ 55°C at pH 
5.5 (Figure 2.9 c-h). The emission intensity manifested a stepwise decrease at ~40°C 
for toxin B and at ~50°C for toxoid B at pH 6.0-7.5.  Emission peak positions of toxin 
B were shifted to lower wavelength at ~30°C prior to a red shift at ~40°C. Toxoid B 
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produced red shifted emission peak positions at ~50°C. These red shifts of the 
emission peak position suggest movement of the indole side chains to a more polar 
environment upon heating. Toxin and toxoid B displayed similar changes in tertiary 
structure with temperature, with the toxoid showing transitions at about 10°C 
temperature (Figure 2.9 d,h) .  
 
2.3.4. ANS Fluorescence  
 fu er evaluated by the appearance 
of prev
The tertiary structure of the proteins was rth
iously buried apolar regions using the ability of ANS to bind to more 
hydrophobic regions of proteins. Protein bound ANS typically displays less solvent-
induced quenching of its fluorescence and therefore increased emission intensity and 
a blue shift of its peak position.  ANS emission peak positions in the presence of four 
proteins at various pH values and temperatures are shown in Figure 2.10. The peak 
positions at 10°C were blue shifted at lower pH which suggests that the toxins and 
toxoids had more solvent exposed apolar regions and were partially unfolded at lower 
pH values. The unfolding of toxin A and exposure of ANS binding moieties upon 
heating to 40°C was manifested by increased ANS fluorescence intensity and a blue 
shift in its emission (Figure 2.10 a,e). Data could not be collected at temperatures 
above 55°C due to extensive emission peak broadening. Toxoid A manifested ANS 
binding events at about 50°C and the data could not be collected above 60°C (Figure 
2.10 b,f).  Toxin and toxoid B displayed a pH dependent temperature of transition 
with low temperature unfolding of protein at lower pH as shown in Figures 2.10 c-i. 
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The extensive broadening of the emission peek seen for the toxin/toxoid B at pH 5.0-
6.0 is manifested by an absence of data at higher temperature. Toxoids A and B again 
displayed about a 10°C delay in their unfolding compared to the toxin.  
 
2.3.5. Dynamic Light Scattering 
The hydrodynamic diameter and polydispersity of the proteins at pH 6.5 and 
ble 2.2. The theoretical diameter (calculated for a sphere 
with a 
10°C are summarized in Ta
partial specific volume of 0.75 ml/mg) is 9.2 nm for toxin A and 8.8 nm for 
toxin B. Toxin A manifests a significantly larger observed diameter compared to the 
calculated size. This can probably be explained by the presence of a small amount of 
high molecular weight aggregated toxin A.43 The toxoids have smaller hydrodynamic 
diameters than their corresponding toxins. This presumably reflects a compaction of 
the toxins from the formaldehyde crosslinking process. The hydrodynamic diameter 
of toxin/toxoid A increased significantly upon heating, with toxin A displaying an 
onset of the thermal transition at about 50°C and toxoid A near 60°C (Figure 2.11 
a,b). The hydrodynamic diameter of toxin B increased stepwise at about 60°C, 
whereas the diameter of toxoid B manifests a much smaller increase at about 70°C 
(Figure 2.11 c,d). Polydispersity of ~0.3 seen in the toxins and toxoids suggest that 
multiple populations are present in each protein. 
 
2.3.6. Empirical Phase Diagrams (EPDs) 
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Structural characterization of C. difficile toxins and toxoids was performed 
with multiple techniques to understand both their aggregation tendencies, as well as 
any changes in secondary and tertiary structure induced by a wide range of pH and 
mperature conditions. 
 structural behavior at different pH values including 
partial 
ates at approximately 55°C. The 
rosslinked toxoid A displayed the following structural states: 1) partially unfolded at 
a transition in form between 50 and 65°C 
and 4)  the presence of insoluble aggregates above 50 – 65°C. 
te
Toxin A displayed diverse
unfolding at pH 5.5, precipitation upon heating at 40-50°C (OD 350 nm), 
tertiary structure alteration near ~40-50°C (ANS binding and second derivative UV 
spectroscopy), and modification of its secondary structure above 50°C. Toxoid A 
precipitated upon heating at 50-70°C, altered its tertiary structure near 50°C and 
modified its secondary structure above 55-60°C. To better define the state of each 
protein as a function of pH and temperature, the OD 350 nm, Trp and ANS 
fluorescence, and CD data were mathematically processed40 and visualized in the 
form of empirical phase diagrams (Figure 2.12). The distinct colors under each 
condition revealed four distinct regions in the phase diagrams. Consideration of the 
individual data allowed assignment of the various regions in the phase diagram to 
individual protein physical states. Based on this analysis, the following structural 
phases of toxin A are proposed: 1) partially unfolded at pH 5.5; 2) natively folded in 
the pH range 6-8; 3) a gradual transition between states in the temperature range 45 – 
55°C and 4) formation of insoluble aggreg
c
pH 5.5; 2) folded in the pH range 6-8; 3) 
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Toxin B also manifested diverse structural characteristics as a function of pH 
partial unfolding at pH 5-5.5, precipitation at pH 5.0-6.0 upon heating to 45-75°C 
(OD 350 nm), changes in tertiary structure at ~40°C (Trp fluorescence, ANS binding 
and second derivative UV spectroscopy), and alterations in secondary structure 
betwee
 
. This work shows that 
n 25 and 45°C. Toxoid B precipitated at pH 5.0-5.5 upon heating to 50-65°C, 
altered its tertiary structure at ~50°C, and changed its secondary structure at from 50-
60°C. 
  The color map for toxin B can than be interpreted as follows: 1) partially 
unfolded at pH 5.0-5.5; 2) unaltered in the pH range 6.0-7.5; 3) changing states within 
the temperature range 45-50°C; 4) becoming insoluble at pH 5.0-6.0 and at 
temperatures above of 45-60°C; and 5) forming soluble aggregates at pH 6.5-7.5 and 
at temperatures above 50°C. The corresponding phase diagram for toxoid B provides 
the related structural description: 1) partially unfolded at pH 5.0; 2) folded in the pH 
range 5.5-7.5; 3) transition at 50-65°C; 4) insoluble aggregate appearance at pH 5.0 
and 5.5 and at temperatures above 55-60°C; and 5) soluble aggregate formation over 
the pH range 6-7.5 at temperatures above 60°C.   
2.4. Disscussion 
These biophysical studies of C. difficile toxins and toxoids A and B permitted 
their systematic characterization over a wide range of pH and temperature. This 
picture is summarized and visualized as EPDs in Figure 2.12
 57
the A 
main presents a unique contribution. The amino-terminal catalytic portion of 
ifferent properties and quite distinct 
thermal behavior. Toxin A displayed a hydrodynamic diameter twice that of toxin B 
although we presume this to be from the presence of a small amount of aggregates. In 
tability, toxin A possesses a tendency to precipitate upon heating at 
all pH v
and B toxins are partially unfolded at low pH (5-5.5) and folded in a 
presumably native form at pH 6-8. These observations are consistent with previously 
reported pH-induced conformational changes of toxin B in early endosomes.23-25 
Circular dichroism studies of the two toxins demonstrate that they possess a complex 
secondary structure with significant helical, ß-sheet and unordered character. The 
observed CD spectra can be explained by the diverse structure of the toxins, in which 
each do
toxin B consists of 543 residues which are arranged in a mixed α/ß-structure of 11 ß-
strands in the core and 21 α-helices on the periphery.26 The 39 repeats in the carboxy-
terminal domain (960 residues) from toxin A are arranged in the form of a ß-selenoid 
fold.22 The absence of information on the middle part of the toxins (~1207 residues) 
permits the extrapolation that the observed large overall helical character of the toxins 
appears to be a contribution from a combination of the amino-terminal domain and 
undefined middle parts of the proteins. 
Even though the A and B toxins have 49% amino acid identity and possess a 
similar domain organization, they display some d
terms of thermal s
alues while toxin B only precipitated at pH 5-6 and formed soluble aggregates 
at pH 6.5-7.5. The observed dissimilarities between the toxins could be related to 
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differences in their structure (carboxy-terminal domain), mechanisms of action 
(enterotoxicity in animals) and their enzymatic activity (velocity and extent)20.  
Crosslinking of the two toxins with formaldehyde led to the formation of 
toxoids with slightly more compact hydrodynamic diameters but surprisingly similar 
properties.  This is especially important in the use of the toxoids as vaccines since it is 
essential to maintain their structural identity as immunogenes. Toxoid A was 
subjected to the formation of insoluble aggregates at more elevated temperatures 
compared to toxin A. Unlike toxin B, toxoid B precipitated upon heating only at pH 
5.0-5.5. The temperature induced secondary and tertiary structural changes in toxoid 
B were delayed by 10-15°C compared to toxin B. These observations suggest that 
formaldehyde crosslinking stabilizes the structure of the C. difficile toxoids. The 
observed superior thermal stability of C. difficile toxoids seen here is consistent with 
previously reported effects of crosslinking on diphtheria toxoid35,38 and could be 
related to both a direct stabilizing effect of crosslinking on folding and inhibition of 
electros
 
tatically driven unfolding (especially due to loss of charges on Lys 
residues).44  
The studies indicate that at pH 6-7.5 below 50°C the toxoids are in a folded 
state. These results can be used to develop more physically stable formulations by 
selection of accelerated stability conditions for subsequent excipient screening studies 




This study of C.difficile toxins A and B demonstrates both similarities 
(secondary structure and low pH induced partial unfolding) and differences (stability 
and thermal behavior) between the two toxins. The superiority of the formaldehyde 
crosslinked toxoids’ thermal stability illustrates the power and utility of this approach 
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Figure 2.2. Shifts in second derivative UV absorption peak position as a function of 
temperature for toxin A (a) and toxoid A (b) at pH 5.5 (□), 6.0 (■), 6.5 (○), 7.0 (●), 
7.5 (∆), 8.0 (▲).The figures represent the following negative peaks: (1) 260 nm, Phe; 
(2) 266 nm, Phe/Tyr; (3) 277 nm, Tyr; (4) 285 nm, Tyr/Trp; (5) 293 nm, Trp. The 
thermal traces represent an average of two measurements, where each data point had 
standard error of less than 0.5. Peak position scale was adjusted to reflect the changes. 
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Figure 2.3. Shifts in second derivative UV absorption peak position as a function of 
temperature for toxin B (a) and toxoid B (b) at pH 5.0 (□), 5.5 (■), 6.0 (○), 6.5 (●), 
7.0 (∆), 7.5 (▲).The figures represent the following negative peaks: (1) 260 nm, Phe; 
(2) 266 nm, Phe/Tyr; (3) 277 nm, Tyr; (4) 285 nm, Tyr/Trp; (5) 293 nm, Trp. The 
thermal traces represent an average of two measurements, where each data point had 





































































































Figure 2.4. High resolution second derivative near UV spectroscopy peak positions 
based empirical phase diagrams for toxin/toxoid A and toxin/toxoid B (the data for 



















igure 2.5. Traces of optical density at 350 nm as a function of temperature for toxin 
A (a) and toxoid A (b) at pH 5.5 (□), 6.0 (■), 6.5 (○), 7.0 (●), 7.5 (∆), 8.0 (▲); and 
 (e), where the 
mperature is encoded by rhomb for toxin A, filled rhomb for toxoid A, square for 







































































































toxin B (c) and toxoid B (d) at pH 5.0 (□), 5.5 (■), 6.0 (○), 6.5 (●), 7.0 (∆), 7.5 
(▲).The thermal traces represent an average of two measurements, where each data 

























































































Figure 2.6.  CD spectra at 10°C for toxin A (a) and toxoid A (b) at pH 5.5 (□), 6.0 
(■), 6.5 (○), 7.0 (●), 7.5 (∆), 8.0 (▲); and toxin B (c) and toxoid B (d) at pH 5.0 (□), 
.5 (■), 6.0 (○), 6.5 (●), 7.0 (∆), 7.5 (▲).The thermal traces represent an average of 

























































































Figure 2.7.  CD trace at 208 nm over the temperature range for toxin A (a) and toxoid 
A (b) at pH 5.5 (□), 6.0 (■), 6.5 (○), 7.0 (●), 7.5 (∆), 8.0 (▲); and toxin B (c) and 
toxoid B (d) at pH 5.0 (□), 5.5 (■), 6.0 (○), 6.5 (●), 7.0 (∆), 7.5 (▲).The thermal 
traces represent an average of two measurements, where each data point had standard 
error of less than 0.25. Midpoints of thermal transitions (e), where the temperature is 
encoded by rhomb for toxin A, filled rhomb for toxoid A, square for toxin B and 








































































































Figure 2.8.  CD spectra at 10°C for toxin B (a) and toxoid B (b) at pH 7.0: before 
melt (□), after melt (■). Each spectrum represents an average of two measurements, 

























































































































































































































Figure 2.9.  Trp fluorescence as a function of temperature: (a-d) normalized emission 
peak intensity change and (e-h) emission peak position change for toxin A (a,e) and 
toxoid A (b,f) at pH 5.5 (□), 6.0 (■), 6.5 (○), 7.0 (●), 7.5 (∆), 8.0 (▲); and toxin B 
,g) and toxoid B (d,h) at pH 5.0 (□), 5.5 (■), 6.0 (○), 6.5 (●), 7.0 (∆), 7.5 (▲).  The 
thermal traces represent an average of two measurements, where each data point had 
standard error of less than 0.5.  




















Figure 2.10.  ANS fluorescence as a function of temperature: (a-d) emission peak 
intensity change and (e-h) emission peak position change for toxin A (a,e) and toxoid 
A (b,f) at pH 5.5 (□), 6.0 (■), 6.5 (○), 7.0 (●), 7.5 (∆), 8.0 (▲); and toxin B (c,g) and 















































































































5 (■), 6.0 (○), 6.5 (●), 7.0 (∆), 7.5 (▲).  The thermal 
s represent an average of two measurements where each data point has standard 
error of less than 0.5. Onsets of thermal transitions (i), where the temperature is 
encoded by rhomb for toxin A, filled rhomb for toxoid A, square for toxin B and 
filled square for toxoid B. 






































































































































































Figure 2.11.  Hydrodynamic diameter as a function of temperature: for toxin A (a), 
toxoid A (b), toxin B (c) and toxoid B (d); MSD Number based(■) and Lognormal 
Number based (◊).  The thermal traces represent an average of two measurements 
where each data point has standard error of less than 1.0. Note that in figure A and B 





























































































































igure 2.12.F  Empirical phase diagram created using OD 350, Trp and ANS 
fluorescence, and CD data for toxins/toxoids A and B (p.unfolded stands for partially 








18 18 28 
Toxin B* 8 35 23 33 
Toxoid B* 7 34 25 33 
 
Table 2.1. Secondary structure assignment with DICHROWEB (estimated error is 
-3%). Note that CD measurements were performed on protein in 5 mM sodium 
phosphate buffer pH 7.0. *Assignment of secondary structure in previously heated 
protein. 
 % 
 helix sheet turns unordered 
Toxin A 32 23 22 22 
Toxoid A 32 25 19 24 
Toxin B 36 21 18 25 
Toxoid B 36 
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Table 2.2. Lognormal Number based mean hydrodynamic diameter and 
olydispersity for toxins/toxoids A and B. 
 
 Mean Diameter (nm) Polydispesity 
Toxin A 24.9 ±0.6 0.298 ±0.05 
Toxoid A 9.6 ±0.7 0.206 ±0.06 
Toxin B 8.4 ±0.5 0.315 ±0.02 





















Clostridium difficile (C. difficile) toxins A and B are responsible for C. 
ifficile-associated disease (CDAD), which manifests itself as nosocomial diarrhea 
nd pseudomembranous colitis.1-5  Treatment of the toxins with formaldehyde results 
 the corresponding toxoids A and B which are completely inactivated and possess at 
ast partial retention of their immunogenicity.6 It has been shown that vaccination 
employing both toxoids is effective in hamsters, healthy adults and patients with 
recurrent CDAD.6-9 Additionally, th n of both free and aluminum salt 
(adjuvant) bound toxoids leads to appropriate immune responses.9,10 The 
administration of both toxoids simultaneously is more effective than administration of 
the individual proteins.11
e 
development, a comprehensive study of their structures as a function of pH and 
temperature has been reported earlier.12 This study identified different physical states 
of the toxoids under the various conditions examined and established their superior 
thermal stability compared to the corresponding toxins. Even though the crosslinked 
toxoids reside in a presumably native-like folded state and exhibit some physical 
stability at pH 6-7.5, improvement of their conformational integrity and a reduction in 
their tendency to aggregate is clearly desirable to produce optimal storage stability. 
In the previously indicated studies, a tendency for both of the toxoids  to form 
aggregates at low pH and elevated temperatures was seen.12 This appears to be the 






Since both the A and B toxoids are current candidates for vaccin
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lly regarded as safe) compounds at various concentrations and in several 
combinations were examined for their ability to inhibit the aggregation of the toxoids. 
Compounds which effectively inhibited aggregation of both toxoids were further 
investigated for their ability to enhance the structural stability of the proteins. To 
identify stabilizing agents for adjuvant bound toxoids, selected exipients were further 
studied for their ability to enhance the thermal stability of adjuvant bound toxoids. 
 
3.2. Experimental methods 
 
3.2.1. Materials 
s A and B were produced in highly purified form by Acambis Inc. 
(Cambridge, MA). The production and purification of this material is described 
elsewhere.7 The concentration of the proteins was determined by UV absorbance at 
280 nm using extinction coefficients of 1.173 for toxoid A and 0.967 for toxoid B. All 
reagents used were of analytical grade and were purchased from Sigma (St. Louis, 
MO). Sodium phosphate buffer (5 mM, pH 5.0, 5.5 and 6.5) containing 150 mM 
NaCl was used for the excipient screening studies. Sodium phosphate buffer (5 mM, 
pH 6.5) containing 150 mM NaCl was used for the agitation and adjuvant studies. Fo
exchange, protein was dialyzed at refrigerator temperature using Slide-A-
Lyzer® Dialysis Cassettes, 10 kDa MWCO (Pierce, Rockford, IL).  
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3.2.2. Excipient Screening Studies 
 
3.2.2.1. Aggregation Assay.  
Approximately 30 GRAS (generally regarded as safe) compounds in 58 variations of 
concentration and in several combinations were screened for their ability to inhibit the 
aggregation of the toxoids. Aggregation of the protein was monitored by optical 
density measurements at 350 nm (OD 350 nm) using a 96-well plate reader (Spectra 
Max M5, Molecular Devices, Sunnyvale, CA). The aggregation assay was performed 
g/ml) and at pH 5.0 for toxoid B (0.5 mg/ml) at 55°C. 
hese conditions were selected based upon the phase boundaries observed in the 
iagrams reported previously.12 Under these conditions, the proteins 
at pH 5.5 for toxoid A (1.2 m
T
empirical phase d
are partially unfolded and spontaneously associate. Thus, any stabilizing influence of 
the excipients that perturbs these two processes can be potentially detected. In a 96-
well plate, the protein was added to wells containing excipient(s) at the corresponding 
pH and the samples were incubated at 55°C for 75 min in case of toxoid A and 55 
min for toxoid B. The optical density of the solutions was monitored at 350 nm every 
5 min. Controls of protein solutions without added compounds and buffer alone with 
excipient(s) were examined simultaneously. The measurements were corrected for 
intrinsic buffer-excipient behavior by subtracting the blanks prior to data analysis. 
Each sample was evaluated in triplicate. Percent inhibition of aggregation was 
calculated employing the following expression: 
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 molar elipticity by Jasco Spectral 
%inhibition of aggregation = 100 - [ ]∆OD350 (E)
∆OD350 (C)
x 100
Where ∆OD350 (E) represents the change in OD 350 nm of the protein in the presence 
of the excipient and ∆OD350 (C) the change in OD 350 nm of the protein without 
excipient.13
 
3.2.2.2. Structural Stability Studies.  
Toxoid solutions were studied at a concentration of 0.2 mg/ml for CD measurements 
and 0.1 mg/ml for fluorescence and UV absorption analysis. No concentration 
dependence was seen over this range. Each sample was evaluated in duplicate to 
ensure reproducibility of the measurements.  
 
3.2.2.2.1. Far-UV Circular Dichroism (CD) Spectroscopy. 
 CD spectra were acquired using a Jasco J-810 spectropolarimeter equipped with a 6-
position Peltier temperature controller. CD spectra were obtained from 260-190 nm 
with a scanning speed of 20 nm/min, an accumulation of 2 scans and a 2 s response 
time. The CD signal at 208 nm was monitored every 0.5°C over a 10 to 85°C 
temperature range employing a temperature ramp of 15°C/hr to study thermal 
transitions (melting curves) of the proteins (in sealed cuvettes with 0.1 cm 
pathlength). The CD signal was converted to
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insic probe 8-Anilino-1-naphthalene sulfonate (ANS). Each sample 
ontained a 20-fold molar excess of ANS to protein. The emission spectra were 
step size of 2 nm and a 1-s integration time after 
lynomial fits using Origin software. 
excipients) was analyzed using a dynamic light scattering instrument (Brookhaven 
 a sigmoid fitting of the melting curves using Origin software. 
3.2.2.2.2. ANS Fluorescence Spectroscopy.  
Accessibility of apolar sites on the proteins was monitored by fluorescence emission 
of the extr
c
collected from 400 to 600 nm with a 
ANS excitation at 372 nm. Emission spectra were collected every 2.5°C with 5 min 
of equilibration over a temperature range of 10 to 85°C. The ANS-buffer baseline at 
each corresponding pH was subtracted from the raw emission spectra. Peak positions 
of the emission spectra were obtained from po
 
3.2.2.2.3. High-Resolution UV Absorbance Spectroscopy. 
 High-resolution UV absorbance spectra were acquired using an Agilent 8453 UV-
visible spectrophotometer. Aggregation of the proteins was studied by monitoring the 
OD at 350 nm every 2.5°C over the temperature range of 10 to 85°C with a 5 min 
incubation (sufficient for equilibrium to be reached) at each temperature.  
 
3.2.2.2.4. Dynamic Light Scattering (DLS).  
The mean hydrodynamic diameter of the proteins at pH 6.5 (alone and in presence of 
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Instrument Corp., Holtzille, NY). The instrument was equipped with a 50 mW diode-
pumped laser (λ = 532 nm) and the scattered light was monitored at 90° to the 
cident beam. The autocorrelation functions were generated using a digital auto-
ic diameter was calculated from the 
SC was performed using a MicroCal VPDSC with autosampler (MicroCal, LLC; 
alone and in the presence 
.2.2.2.6. Agitation studies.  
g/ml were studied in the presence and 
in
correlator (BI-9000AT). The hydrodynam
diffusion coefficient by the Stokes-Einstein equation using the method of cumulants 
(lognormal number based). The data were fit to a non-negatively constrained least 
squares algorithm to yield multi-modal distributions (MSD). The instrument was 
equipped with a temperature-controlled circulating water bath RTE111 (Neslab, 
Newington, NH) and the hydrodynamic diameter was monitored over a temperature 
range of 10 to 85°C. 
 
3.2.2.2.5. Differential Scanning Calorimetry (DSC).  
D
Northampton, MA). Thermograms of toxoids (0.5 mg/ml) 
of excipient(s) were obtained from 10-90°C using a scan rate of 60°C/hr. The filled 
cells were equilibrated for 15 min at 10°C before beginning each scan. Thermograms 
of the buffer alone were subtracted from each protein scan prior to analysis. 
 
3
Toxoid solutions at a concentration of 0.4 m
absence of the excipients. Protein samples (0.4 ml) were placed in 1.5 ml centrifuge 
tubes and shaken in a rotator (Thermomixer R, Eppendorf AG, Hamburg, Germany) 
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at 300 rpm for 72 hrs at a constant temperature of 4°C. The concentration of the 
protein and OD 350 nm were measured before and after the rotation to evaluate 
adsorption to vessel walls and aggregation. Samples were centrifuged for 10 min at a 
speed of 10,000xg at 4°C and the concentration and OD 350 nm of the supernatant 
were measured to detect formation of insoluble aggregates. The structure of the 
proteins was evaluated by CD.  Each sample was measured in duplicate.  
 
3.2.3. Adjuvant Studies 
 
3.2.3.1. Adsorption to Aluminum Hydroxide (Alhydrogel®). 
 to adsorb to Alhydrogel® (Brenntag Biosectror, 






ind to the Alhydrogel® in the presence of excipients was determined by the same 
lhydrogel® was added to the protein-excipient solution. 
 The ability of the toxoids
Frederickssund, Denmark) at various concentratio
determined by constructing a binding isotherm. The protein solutions in the presen
of 0.4 mg/ml Alhydrogel® were tumbled in an end-over-end tube rotator a
refrigerator temperature for 20 min. The samples were centrifuged at 14,000xg for 3
s to pellet the adjuvant. The value of the concentration of the protein remaining in the
supernatants was used for the construction of binding curves. The ability of p
b
procedure. In this case, the A
 
3.2.3.2. Desorption of toxoids from Alhydrogel®. 
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 Desorption of the proteins from Alhydrogel® was evaluated in presence of 2 M NaCl. 
The toxoid Alhydrogel® pellets were prepared as described above. The pellets were 
washed with buffer (pH 6.5) to remove protein present in the supernatant prior to 
addition of the NaCl solution. The Alhydrogel® solutions were tumbled in an end-
over-end tube rotator at refrigerator temperature for 20 min. The samples were 
centrifuged at 14,000xg for 30 s to pellet the adjuvant. The concentration of the 
rotein in the supernatants was used for the construction of desorption isotherms. 
.2.3.3. Stability of Toxoids Bound to Alhydrogel®.  
as monitored with DSC 
.3.1. Excipient Screening Studies 
ounds to prevent/delay aggregation, 




The thermal stability of the toxoids bound to Alhydrogel® w
using a MicroCal VP-AutoDSC (MicroCal, LLC, Northampton, MA). Toxoids at 0.5 
mg/ml were bound to 0.4 mg/ml Alhydrogel® by the procedure described above. 
Thermorgams of the toxoids were obtained from 10 to 90°C with a scanning rate of 
60°C/hr. The samples were equilibrated for 15 min at 10°C before each scan. 
Thermograms of the Alhydrogel® alone were subtracted from each protein/adjuvant 
scan prior to analysis.  
 
3.3. Results and disscussion 
 
3
To investigate the ability of GRAS comp
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(incubation at 55°C). Aggregation of the toxoids was monitored in a high-throughput 
fashion by monitoring changes in OD at 350 nm during the incubation time (75 min 
for toxoid A and 55 min for toxoid B). The turbidity changes were further used to 
calculate % of aggregation inhibition and are summarized in Table 3.1 for toxoid A 
and Table 3.2 for toxoid B.  
High-throughput aggregation assays of toxoid A found that more than half of 
the excipients either delayed or prevented increases of OD 350 nm over time and led 
 inhibition of aggregation by 90% or more (Table 3.1). Among the excipients 
% tween 80, 0.3 M histidine and 
he presence of 0.3 M histidine or 0.2 M sodium citrate led to 
stantaneously high OD 350 nm. Another 20 compounds more gradually induced 
onitored. Extremely high increases in OD 350 nm were 
bserved in presence of 0.015 M calcium chloride, 0.15 M ascorbic acid and 0.3 M 
to
examined,  2.5% albumin, 2.5% α-cyclodextrin, 0.1
0.3 M lysine led to instantaneously high OD 350 nm values which suggests that the 
toxoid A is insoluble under this conditions. The aggregation of the toxoid A was also 
significantly enhanced in the presence of 16 other excipients, among which 25 and 50 
mM arginine/glutamine mixture, 0.3 M arginine and 0.3 M proline were especially 
potent.  
Inhibition of toxoid B aggregation by 90% or more occurred in presence of 15 
excipients (Table 3.2). T
in
aggregation during the time m
o
arginine.  
In many cases, the aggregation of both toxoids was facilitated by the same 
excipients (Table 3.1 and 3.2). In contrast, 5% 2-OH propyl γ-CD, 0.01% and 0.1% 
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tween 20, 0.15M aspartic acid and 0.3M guanidine facilitated aggregation of toxoid 
B, but not toxoid A. In addition, aggregation in the presence of 0.015 M calcium 
chloride was much greater for toxoid B than toxoid A. This may be related to the 
known increased thermal stability of the toxin A C-terminal domain in the presence 
of calcium chloride.14 The dissimilarities between the toxoids in their responses to 
solute i
 0.1% tween 80 and 0.1% pluronic F-68) were further studied for their ability 
to stab
ry structure change only in presence of 20% sucrose while the rest of the 
excipie
nduced aggregation is presumably related to structural differences between the 
corresponding toxins.3,15 An absence of inositolphosphates among compounds studied 
suggests that the observed aggregation of the toxoids does not involve autocatalytic 
cleavage.16 Most of the carbohydrates, detergents and cyclodextrins examined 
inhibited aggregation of the toxoids. The following excipients were found to 
efficiently inhibit aggregation of both of the toxoids: 20% trehalose, 20% sucrose, 
10% sorbitol, 10% dextrose and 20% glycerol. 
  The above mentioned carbohydrates, sorbitol, glycerol and two surfactants 
(0.05% /
ilize the protein’s secondary and tertiary structure at pH 6.5 by monitoring 
ANS fluorescence, CD signal changes upon heating and DSC (Figure 3.1 and 3.2). 
Toxoid A in the presence of 20% sucrose and 20% trehalose produced an earlier onset 
of secondary structure change, whereas the rest of the excipients delayed the thermal 
transition by ~2°C (Figure 3.1a). Surprisingly, Toxoid B manifested an earlier onset 
of seconda
nts delayed the thermal transition by ~1°C (Figure 3.2a).  The early onset of 
the toxoids’ secondary structure change in the presence of trehalose and/or sucrose 
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could be explained by stabilization of partially unfolded state(s) by the solutes. 
Additionally, the possibility that the toxoids are partially unfolded upon binding to 
their C-terminal carbohydrate recognition sequence repeats by polysaccharides17 can 
not be ruled out. In the case of the structural destabilization by the second 
mechanism, the dissimilarity of the two toxoids behavior in the presence of trehalose 
could be related to structural differences between toxoids (the C-terminal domain 
possesses 30 repeats in toxoid A and 19 repeats in toxoid B)15. It is interesting to note 
that the monosaccharide (dextrose) had a stabilizing effect on the secondary stricture 
of both toxoids. Temperature-induced unfolding of both toxoids and associated 
binding of ANS was not influenced by the presence of the compounds (Figure 3.1b, 
3.2b). The effect of the detergents on the temperature induced unfolding of the 
toxoids was monitored with DSC and did not appear to be significant (Figure 3.1c, 
3.2c and table 3.3). These observations suggest that the excipients do not strongly 
stabilize the structure of the toxoids by the well described preferential exclusion 
mechanism18,19, but rather inhibit their aggregation by other mechanisms, such as by 
direct blocking of the protein/protein interactions that are responsible for protein 
association. 
To study the effect of a combination of the more active agents on secondary 
structure, the results from a mixture of sorbitol, dextrose and tween 80 was 
characterized by monitoring the toxoid’s thermal transitions with CD and aggregation 
with OD 350 nm (Figures 3.3 and 3.4). The heating of solutions of tween 80 (0.05% 
or 0.1%) alone in the presence of sorbitol and/or dextrose lead to changes in its 
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micelle structure, which were manifested by a decrease in the CD signal and 
increased light scattering as monitored by OD 350 nm (Figure 3.5). The concentration 
of the excipients had an approximately linear effect on the temperature of the thermal 
transitions (Figure 3.6). This supports the hypothesis that the excipients prevent 
aggregation by directly inhibiting protein association. The effects of the excipients on 
the thermal transition are summarized in Table 3.4 and 3.5. The combination of 10% 
dextrose and 10% sorbitol in the presence or absence of 0.05% tween 80 tends to 
delay the midpoint of the thermal transition of both the toxoids to the greatest extent 
(~4°C for toxoid A and ~10°C for toxoid B) (Figure 3.3). This can be explained by 
either a synergistic effect and/or the higher total concentration of the stabilizing 
compounds. In the case of toxoid B, the onset temperature of the transition was not 
delayed in the presence of combinations of agents, but the midpoint of the thermal 
transition was significantly delayed. This could be related to a more gradual 
unfolding of toxoid B in the presence of the two or more excipients. Toxoid A 
manifested a significant delay of aggregation (monitored with OD 350 nm) in 
presence of stabilizing compounds (Figure 3.4a). The hydrodynamic diameter of the 
toxoids in the presence and absence of the excipients was also monitored by DLS 
(Figure 3.7). Toxoid A manifested a delayed onset of the previously observed 
hydrodynamic diameter increase in the presence of the excipients (Figure 3.7 a-c), 
whereas a smaller effect was seen with toxoid B (Figure 3.7 d-f). These observations 
suggest that the particular combination of potential vaccine excipients tested here 
stabilizes protein structure by both a preferential hydration mechanism and direct 
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inhibition of protein association. The use of such stabilizing compounds could 
potentially increase the physical stability of the toxoids during storage. 
 
3.3.1.1. Agitation studies 
The effect of agitation on toxoid physical stability was studied by monitoring 
protein adsorption to the walls of storage vials, formation of insoluble aggregates and 
changes in protein thermal stability. An insignificant change in protein concentration, 
OD 350 nm and in CD melts in the presence and absence of the excipients (not 
illustrated) indicated that the toxoids do not undergo major physical changes upon 
application of this agitation-based stress.  
 
3.2.3. Adjuvant Studies 
Adjuvant binding isotherms revealed that the toxoids efficiently bind to 
Alhydrogel® at low concentrations with binding saturated at higher protein 
concentration (Figure 3.8a). The toxoids at 0.5 mg/ml are 95% or more bound to 
Alhydrogel®, which allows use of DSC to directly monitor the stability of protein on 
the surface of the adjuvant. The absence of toxoids desorption upon addition of 2 M 
NaCl indicates that the interaction of toxoids with Alhydrogel® is not solely 
electrostatic as is often observed in protein/Aluminum hydroxide interactions20-22 
(Figure 3.8b).  
Upon binding to Alhydrogel®, toxoid A manifests no detectable change in its 
thermal stability, whereas adjuvant bound toxoid B demonstrates a decrease of the 
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Tm by ~1.4°C.  The fraction of Alhydrogel® bound toxoid is somewhat reduced in the 
presence of the most of the excipients (Table 3.6 and 3.7). This suggests that the 
excipients partially interfere with toxoid binding to Alhydrogel® perhaps by direct 
e protein and/or adjuvant. The thermal stability of the 
protein
he thermal stability of toxoid B alone. 
Additionally, tween 80 had a stabilizing effect only in case of adjuvant bound toxoid 
xtrose (10%) had a stabilizing effect on the thermal stability 
of both
3.4. Conclusions 
A systematic approach to stabilizer screening resulted in the identification of 
excipients which improved the thermal stability of both the A and B Clostridium 
difficile toxoids.  Studies of Alhydrogel® bound toxoids in the presence of selected 
excipients identified conditions that produced improved physical stability of the 
adjuvant bound proteins. This study also generated information concerning the 
interaction with either th
s bound to Alhydrogel® in the presence and absence of the excipients is 
summarized in Table 3.6 for toxoid A and Table 3.7 for toxoid B. The presence of the 
excipients perturbed the thermal stability of adjuvant bound toxoids either by 
decreasing or increasing the transition temperature. A decrease of thermal stability 
was seen in both toxoids in presence of 10% sorbitol, whereas the presence of 10% 
sorbitol and 10% dextrose decreases t
B. On the other hand, de
 toxoids.   Interestingly, the combination of the three excipients (10% sorbitol, 
10% dextrose with 0.05% or 0.1% tween 80) tends to raise the thermal transition of 
both adjuvant bound toxoids by 3-4°C and might therefore be a candidate for further 
formulation development.  
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toxoids physical behavior under a range of conditions (temperature, solute) that could 
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igure 3.1.  Studies of solute effects on the structural stability of toxoid A (x) in 
), 20% sucrose (■), 10% sorbitol (○), 10% dextrose (●), 
20% glycerol (∆), 0.05% tween 80 (▲), 0.1% pluronic F68 (◊): (a) CD signal at 208 
nm; (c) ANS emission intensity (d) ANS emission peak position and (b) DSC 
thermogram. The thermal traces represent an average of 2 measurements, where each 
data point had a standard error of less than 0.5. 



















































































































































































































Figure 3.2.  Studies of solute effects on the structural stability of toxoid B (x) in 
presence of 20% trehalose (□), 20% sucrose (■), 10% sorbitol (○), 10% dextrose (●), 
20% glycerol (∆), 0.05% tween 80 (▲), 0.1% pluronic F68 (◊): (a) CD signal at 208 
nm; (c) ANS emission intensity (d) ANS emission peak position and (b) DSC 
thermograms. The thermal traces represent an average of 2 measurements. Each data 
point had a standard error of less than 0.5. 
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of toxoid A (x) in presence of 10% sorbitol and 0.05% tween 80 (□), 10% dextrose 
and 0.05% tween 80 (■), 10% sorbitol, 10% dextrose and 0.05% tween 80 (○), 10% 
dextrose and 10% sorbitol (●): (a) monitored by the CD signal at 208 nm and (b) OD 
350 nm. The thermal traces represent an average of 2 measurements, in which each 





































Figure 3.4.  Studies of combinations of solutes and their effect on the thermal 
stability of toxoid B (x) in presence of 10% sorbitol and 0.05% tween 80 (□), 10% 
dextrose and 0.05% tween 80 (■), 10% sorbitol, 10% dextrose and 0.05% tween 80 
(○), 10% dextrose and 10% sorbitol (●): (a) monitored by CD signal at 208 nm and 
(b) OD 350 nm. The thermal traces represent an average of 2 measurements, where 








































































































































































igure 3.5.  Studies of the properties of the tween 80 (□) in presence of 10% dextrose 
es represent an average of 2 
easurements, where each data point had standard error of less than 0.5. 
 
F
(■), 10% sorbitol (○), 10% dextrose and 10% sorbitol (●) as a function of 
temperature:  208 nm CD signal of 0.05% tween 80 (a) and 0.1% tween 80 (b); OD 
350 nm for  0.05% tween 80 (c) and 0.1% tween 80 (d); hydrodynamic diameter 
MSD Number based (filled square) and Lognormal Number based (filled rhomb) for 
0.05% tween 80 (e) and 0.1% tween 80 (f).  Sizes of > 1µm are not accurate given the 














































































Figure 3.6.  Studies of the effect of solute concentration on the midpoint of the 
thermal transition (Tm) monitored with CD 208 nm signal for toxoid A (a) and toxoid 
B (b) in presence of sorbitol and 0.05% tween 80 (♦), dextrose and 0.05% tween 80 
(■), sorbitol, dextrose and 0.05% tween 80 (▲), sorbitol, dextrose and 0.1% tween 80 








































































































































orbitol and 10% dextrose; (c,f) protein in presence of 
0% sorbitol, 10% dextrose and 0.05% tween 80. The thermal traces represent an 
verage of 2 measurements, where each data point had a standard error of less than 
.5 
Figure 3.7. The hydrodynamic diameter as a function of temperature for toxoid A (a-
c) and toxoid B (d-f) where the filled squares represent MSD number based diameter 
and filled rhomboids represent the lognormal number based diameter. Sizes of > 1 
µm are not accurate given the nature of DLS measurements. (a,d) protein alone; (b,e) 









































Figure 3.8.  Alhydrogel® binding studies: (a) sorption isotherm and (b) desorption 






























0 50 100 150 200 250 300 350 400 450 500







































Table 3.1. Effect of GRAS excipients on toxoid A aggregation. Compounds which 
elay/preve bition values; 










% Inhibition of 
aggregation 
lbumin 2.5% 103* Glycerol 10% 88 
 Cyclodextrin 2.5% 101* 2-OH propyl γ-CD 10% 81 
ween 80 - 0.1% 100* Tween 20 - 0.05% 73 
ietanolamine 0.3M 100 Tween 80 - 0.05% 67 
odium Citrate 0.1M 100 Aspartic Acid 0.15M 65 
orbitol 10% 100 Tween 20 - 0.1% 64 
istidine 0.3M 100* Pluronic F-68 0.05% 50 
ucrose 10% 100 Tween 20 -  0.01% 37 
rehalose 10% 100 Dextran Sulfate 0.04 mg/ml 30 
uanidine 0.3M 99 Brij 35 0.05% 26 
orbitol 20% 99 Dextran Sulfate 0.004 mg/ml 16 
extrose 20%  2-OH propyl γ-CD 5% 10 
extrose 10% 99 Albumin 5% 9 
rehalose 20% 99 Brij 35 0.01% -2 
odium Citrate 0.2M 99 Calcium Chloride 0.015M -7 
lycerol 20% 98 Pluronic F-68 0.01% -14 
ween 80 - 0.01% 98 Gelatin 5% -46 
lbumin 1% 98 Malic Acid 0.15M -52 
actose 20% 98 Lactic Acid 0.15M -72 
annitol 10% 97 Gelatin 2.5% -74 
ucrose 20% 97 Glutamic Acid 0.15M -77 
luronic F-68 0.1% 96 Dextran T40 0.003 mg/ml -87 
-OH propyl ß-CD 10% 96 Glycine 0.3M -88 
-112 
extran T40 0.03 mg/ml 93 Arginine 0.3M -265 
% 92 Arg/Glu 50mM each -426 
Lysine 0.3M 89* Arg/Glu 25mM each -463 
Uncertainties are on the order of ±1%. *High initial OD 350 nm. 





























2-OH propyl ß-CD 5% 96 Dextran Sulfate 0.1 mg/ml -88 
Dextran T40 0.08 mg/ml 95 Ascorbic Acid 0.15M -99 




Table 3.2. Effect of GRAS excipients on toxoid B aggregation. Compounds which 
xcipient  
on % Inhibition of 
Excipient  
on % Inhibition of 













CD 5% g/ml 








certainties are o  order  OD 350 
delay/prevent aggregation have positive % of aggregation inhibition values; 










Histidine 0.3M 100* Dextran T40 0. 25 
Tween 80 - 0.1% 100 2-OH propyl γ-CD 10% 12 
Tween 80 - 0.05% 100 Brij 35 0.05% 10 
Albumin 1% 99 Pluronic F-68 0.05% 6 
Dextrose 20% 99 Glycerol 10% 4 
Albumin 5% 98 Dextran Sulfate 0. 3 
Sodium Citrate 0 98* Dextran Sulfate 0.004 2 
Trehalose 20% 98 Tween 20 - 0.05% 0 
Sodium Citrate 0 97 2-OH propyl γ-CD 5% -5 
Sorbitol 20% 97 Tween 20 -  0.0 -5 
Sucrose 20% 96 Pluronic F-68 0.01% -8 
Dietanolamine 96 Tween 20 - 0.1% -13 
Dextrose 10% 95 Brij 35 0.01% -25
Sorbitol 10% 92 Glycine 0.3M -26
Albumin 2.5% 87 Gelatin 2.5% -36
2-OH propyl ß- 79 Dextran Sulfate 0.1 m -38 
2-OH propyl ß-CD 78 Arg/Glu 50m -39 
Mannitol 10% 76 Glutamic Acid 0.15 -41 
Sucrose 10% 71 Arg/Glu 25mM each -42 
Glycerol 20% 71 Aspartic Acid -50 
Trehalose 10% 69 Gelatin 5% -56 
Pluronic F-68 0.1% 68 Proline 0.3M -57 
Brij 35 0.1% 63 Dextran T40 0. -59 
Lactose 20% 52 Lactic Acid 0.15M -80 
Malic Acid 0.15M 44 Guanidine 0.3M -96 
Tween 80 - 0. 40 Calcium Chloride 0.015M -141 
Lactose 10% 39 Ascorbic Acid 0 -223 
Lysine 0.3M 37 Arginine 0.3M -280 
Un n the  of ±1%. *High initial nm. 
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Table 3.3. Effect of solutes (detergents) on the thermal stability of toxoid A and B. 
The thermal stability (Tm) was monitored by DSC. The Tm is the temperature 




59.8 ± 0.0 
 0.05%  80 
A + 0.1%p ic F68
  0.0 
id B + 0.05% en 80 
oid B + 0.1%p nic F68
Tm (°C) 
Toxoid A 
Toxoid A +  tween 59.1 ± 0.4 
Toxoid luron  59.1 ± 0.4 
Toxoid B 55.8 ±
Toxo  twe 56.1 ± 0.3 
Tox luro  58.0 ± 0.3 
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Table 3.4. Effect of excipients on the toxoid A midpoint of the thermal transition 
temperature (Tm). The thermal transition was monitored by the CD signal at 208 nm 
as a function of temperature. Each measurement was conducted in duplicate and has 
0.5°C of uncertainty. 




 Toxoid A 8 0.0 59.
 20% trehalose -0.5 59.4 
 20% sucro 1 3.3 se 63.
 20% glyce 4 2.6 rol 62.
 0.1% plur 1 1.3 onic F68 61.
 10% sorbi 4 2.6 tol 62.
 10% dextros 2.6 e 62.4 
 0.05% Tw 9 0.0 een 80 59.
 5% sorbitol + 0.05% Tween 80 60.4 0.6 
 10% sorbitol + 0.05% Tween 80 62.3 2.5 
 15% sorbitol + 0.05% Tween 80 62.4 2.6 
 5% dextrose + 0.05% Tween 80 60.2 0.4 
 10% dextrose + 0.05% Tween 80 62.3 2.5 
 15% dextrose + 0.05% Tween 80 62.5 2.7 
 2.5% sorbitol + 2.5% dextrose +  0.05% Tween 80 60.2 0.4 
 5% sorbitol + 5% dextrose +  0.05% Tween 80 61.3 1.5 
 10% sorbitol + 10% dextrose +  0.05% Tween 80 63.5 3.7 
 0.1% Tween 80 59.0 -0.8 
 10% sorbitol + 0.1% Tween 80 60.6 0.7 
 10% dextrose + 0.1% Tween 80 61.5 1.7 
 2.5% sorbitol + 2.5% dextrose +  0.1% Tween 80 60.0 0.2 
 5% sorbitol + 5% dextrose +  0.1% Tween 80 60.5 0.7 
 10% sorbitol + 10% dextrose +  0.1% Tween 80 62.1 2.3 
 2.5% sorbitol + 2.5% dextrose 60.8 0.9 
 5% sorbitol + 5% dextrose 61.7 1.8 
 10% sorbitol + 10% dextrose  63.9 4.0 
 15% sorbitol + 15% dextrose 64.6 4.8 
 20% sorbitol + 20% dextrose 66.6 6.7 
 20% sorbitol + 10% dextrose 64.9 5.1 
 10% sorbitol + 20% dextrose 50.1 -9.7 
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Table 3.5. Effect of excipients on the toxoid B midpoint of thermal transition 
temperature (Tm). The thermal transition was monitored by the CD signal at 208 nm 
as a function of temperature. Each measurement was conducted in duplicate and has 
0.5°C of uncertainty. 
 presence of excipient(s) T Tm difference 
~
 
 Toxoid B in m 
 Toxoid B 55 0..8 0 
 20% trehalose 60 4.5.3  
 20% sucrose - - 
 20% glycerol 58 2.8.6  
 0.1% pluronic F68 56 0.4.2  
 10% sorbitol 56 0.8.6  
 10% dextrose 57 1.6.3  
 0.05% Tween 80 55 -0..1 7 
 5% sorbitol + 0.05% Tween 80 56 0.9.7  
 10% sorbitol + 0.05% Tween 80 63 7.4.2  
 15% sorbitol + 0.05% Tween 80 64 8.2.0  
 5% dextrose + 0.05% Tween 80 59 3.3.1  
 10% dextrose + 0.05% Tween 80 70 15..8 0 
 2.5% sorbitol + 2.5% dextrose +  0.05% Tween 80 56 0.9.7  
 5% sorbitol + 5% dextrose +  0.05% Tween 80 63 7.7.5  
 10% sorbitol + 10% dextrose +  0.05% Tween 80 69 13..1 3 
 0.1% Tween 80 53 -2..6 2 
 10% sorbitol + 0.1% Tween80 58 2.7.5  
 10% dextrose + 0.1% Tween80 62 6.9.6  
 2.5% sorbitol + 2.5% dextrose +  0.1% Tween 80 60 4.2.0  
 5% sorbitol + 5% dextrose +  0.1% Tween 80 56 0.8.5  
 10% sorbitol + 10% dextrose +  0.1% Tween 80 60 5.1.8  
 5% sorbitol + 5% dextrose 56 0.7.5  
 10% sorbitol + 10% dextrose  65 9.6.3  
 15% sorbitol + 15% dextrose 60 4.4.1  
 20% sorbitol + 20% dextrose 63 7.3.1  
 20% sorbitol + 10% dextrose 38 -17.0 .8 
10% sorbitol + 20% dextrose 61 5.5.2  
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Table 3.6. Thermal stability of  toxoid A bound to Alhydrogel in the presence and 
tion with an uncertainty of 1%. Each condition was studied in 
uplicate.   






58.8 ± 0.4 0.1 
58.7 ± 0 - 
l 52.4 ± 1 -6.2 
60.6 ± 0 2.0 
58.7 ± 0 0.0 
 62.9 ± 0 4.2 
e + 0.05% Tween 80 63.1 ± 1 4.2 
 + 0.1% Ttween 80 62.0 ± 3.3 
59.3 ± 0 0.7 
59.5 ± 1 0.8 
absence of excipient(s) (unless specified otherwise). The thermal stability (Tm) was 
monitored by DSC, with the Tm indicating the temperature corresponding to the peak 
position of the thermal transition. The percent of toxoid bound to adjuvant was 







Toxoid A not bound - 
Toxoid A 96 .3 
10% sorbito 81 .5 
10% dextrose 86 .5 
0.05% Tween 80 93 .1 
10% sorbitol + 10% dextrose 77 .0 
10% sorbitol + 10% dextros 81 .2 
10% sorbitol + 10% dextrose 74 1.3 
10% sorbitol + 0.05% Tween 80 86 .8 
10% dextrose + 0.05% Tween 80 85 .1 
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Table 3.7. The thermal stability of toxoid B bound to Alhydrogel in the presence and 
absence of solute(s) (unless specified otherwise). The thermal stability (Tm) was 
monitored by DSC. The Tm indicates the temperature corresponding to the peak 
position of the thermal transition.   The percent of protein bound to adjuvant was 
measured under each condition with an uncertainty of 1%. Each condition was 















Toxoid B not bound - 56.2 ± 0.4 1.4 
Toxoid B 99 54.8 ± 0.5 - 
10% sorbitol 92 52.5 ± 1.4 -2.2 
10% dextrose 96 57.9 ± 0.2 3.1 
0.05% Tween 80 96 58.2 ± 0.6 3.4 
10% sorbitol + 10% dextrose 95 54.2 ± 0.9 -0.5 
10% sorbitol + 10% dextrose + 0.05% Tween 80 99 58.0 ± 2.8 3.3 
10% sorbitol + 10% dextrose + 0.1% Tween 80 77 58.7 ± 1.0 3.9 
10% sorbitol + 0.05% Tween 80 96 58.5 ± 1.0 3.8 












Stability of Human Growth Hormone in Lyophilized Formulations –
and ole bilEffect of Protein-Excipient Interactions  M cular Mo ity 
 116
4.1. Introduction 
Studies of lyophilized protein formulations have suggested that excipients 
ble to hydrogen bond (H-bond) to proteins can enhance their stabilities.  Excipients 
re thought to H-bond to proteins during secondary drying which leads to the 
reservation of protein structure and ultimately enhancement of stability during 
orage.1  Although, studies have shown that some H-bonding excipients produce 
better protein stability than other  of our knowledge there are no 
systematic studies that establish direct relationship between the magnitude of protein-
excipient interactions, structural relaxation of the dry amorphous matrix and the 
stability of a protein. A better understanding of the relationships between the physical 
characteristics of amorphous matrices and the stability of proteins in solid 
for of 
significant interest.   
 To better understand the influence of the extent of protein-excipient 
interactions and molecular relaxation of any accompanying matrix on chemical (e.g. 
deamidation, oxidation, etc.) and physical (e.g. conformational integrity, formation 
of soluble and insoluble aggregates, etc.) protein stability, a model system was 
selected. The protein, human growth hormone (hGH), in the presence of two 
carbohydrates commonly used for lyophilization (sucrose and trehalose) was 
formulated in a 1:2 protein to excipient weight ratio. It has been shown previously 
that the 1:2 hGH to excipient weight ratio is effective in stabilizing the protein and 






s,2 to the best
mulations may aid in development of more stable formulations and therefore be 
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structural isomers (possessing the same molecular formula but different topological 
 on scanning rate (utilizing DSC) and was used to calculate 
structures) and contain equal numbers of H-bond donors and acceptors. In addition, 
sucrose forms an amorphous matrix with a lower glass transition temperature (Tg) 
and has a tendency to form more homogeneous mixtures with polymers compared to 
trehalose.4 These similarities and differences make sucrose and trehalose ideal 
candidates for obtaining a better understanding of the role of protein-excipient 
interactions as they are related to amorphous/amorphous phase separations and 
structural relaxation of amorphous matrices.  
 The extent of interaction between hGH and excipient were measured using a 
number of different techniques including ISC, DSC, WSA and FTIR. The use of 
these methods to characterize protein solids is descried in detail elsewhere.2,4-8 The 
fragility of the amorphous matrix was determined from the dependence of the glass 
transition temperature
initial relaxation times employing the Vogel–Tammann–Fulcher (VTF) equation.9 
Additionally, solutions of hGH with and without sucrose and trehalose were 
characterized by a variety of techniques to see to what extent solution properties 
might be predictive of the protein in the lyophilized solid state.  
 




Human growth hormone (hGH) was provided by Genentech Inc. (South San 
Francisco, CA) in highly purified form. All reagents were of analytical grade and 
were purchased from Sigma (St. Louis, MO).  The protein was dialyzed into 
potassium phosphate buffer (5 mM) at pH 7.4 using sulfur and heavy metal free 
Spectra/Por dialysis membranes (7) with MWCO of 10 kDa at refrigerator 
temperature. Subsequently, concentration of the protein to 12 mg/ml resulted in a 
stock solution which was diluted with buffer containing the excipient (sucrose or 
trehalose) to obtain solutions with the desired protein concentration. As shown in 
g. oncentration and 
olume) to obtain a lyophilized solid with one component. Lyophilization was 
age Lyophilizer (Gardiner, NY). The vials were loaded 
t ambient temperature and a shelf temperature of -40°C was maintained for 2 h. A 
 of 60 mTorr was applied and the shelf temperature was maintained 
at -40°C for additional 5 h. The temperature was ramped to -35°C over 5 h and was 
previous studies of hGH in lyophilized formulations,10 solutions at pH of 7.4 lead to 
adequate stability of the protein in the solid state and therefore were selected for these 
studies.  
 
4.2.1.1. Lyophilization Procedure 
Lyophilization vials (5 cc Fisher brand amber glass with linerless screw tops) were 
filled with 1 ml of solution containing hGH and sucrose or trehalose in a 1:2 weight 
ratio (each vial contained 1 mg/ml of protein and 2 mg/ml of excipient).  Protein or 
sugar alone was lyophilized under the same conditions (e. c
v




held at -35°C for 2 h, ramped to -10°C over 25 min and held at -10°C for 10 h.  The 
initial steps of primary drying were performed at temperatures below Tg’ (-28.5°C ± 
0.3 for hGH/sucrose and -28.0°C ± 0.4 for hGH/trehalose). The Tg’ values (onsets of 
the thermal transition) were measured with a Q100-DSC (TA instruments Inc., New 
Castle, DE). Approximately 20µL samples in hermetically sealed aluminum pans 
were frozen to -60°C and subsequently heated to 0°C at 10°C/min.    Secondary 
drying was performed by increasing the shelf temperature to 15°C over 30 min, 
holding it for 3 h with a subsequent ramp to 30°C over 5 min and a hold at 30°C for 6 
h. This lyophilization cycle resulted in visually elegant amorphous lyo-cakes with less 
than 1% residual moisture. The absence of crystallization was confirmed with powder 
X-ray diffraction (D8 Advance, Bruker AXS) and the moisture content was measured 
y a Karl-Fischer coulometric titration method11 (DL36 KF Coulometer, Columbus, 
 were placed in a glove box (Labconco), purged 
b
OH). Vials with lyophilized solids
with Argon for 2 hours, parafilm caped and stored in desiccators to assure absence of 
oxygen in the headspace to minimize oxidative degradation of hGH. 
 
4.2.2. Extent of protein-excipient interaction 
 
4.2.2.1. Isoperibol Solution Calorimetry (ISC).  
The enthalpies of dissolution of hGH/excipient physical mixtures and colyophilized 
samples were measured utilizing a Hart Scientific isoperibol solution calorimeter 
 120
(Model 4285). Measurements of dissolution enthalpies and calculation of the protein-
excipient enthalpy of interaction are described in detail elsewhere.8,12
 
4.2.2.2. Water Sorption Analysis (WSA). 
 Hydration isotherms of the samples were monitored with a SGA-100 symmetric 
vapor sorption analyzer (VTI Corporation, Hialeah, FL). Prior to each measurement, 
the samples were dried in vacuum for 24 h. Water uptake by the lyophilized 
hGH/sugar mixture and the single component (protein or sugar) solids was measured 
during a stepwise increase of water partial pressure by 3% over a hydration range of 
10-90% at 25°C. The humidity level was equilibrated for 5 min at each step. 
Interaction parameters were calculated over the range of 10-40% relative humidity 
(RH) based on theoretical and observed hydration isotherms as described 
previously.5,6
 
4.2.2.3. Differential Scanning Calorimetry (DSC).  
The Tg values (onsets of the thermal transition) were measured with Q100-DSC (TA 
-5 mg) were sealed in aluminum pans 
A instruments) and were equilibrated for 5 min at -20°C. The temperature was 
 to 200°C at a rate of 1°C/min. The 
 
instruments Inc., New Castle, DE). Samples (2
(T
modulated by ± 0.5°C every 100s while ramped
theoretical Tg values for hGH/excipient (sucrose or trehalose) formulations were 






where Tg12 is a Tg of a mixture, w1 and w2 are the mass fractions of each component, 
and Tg1 and Tg2 are the respective glass transition temperatures. Calculation of the 
constant K was performed according to the Simha-Boyer rule with an assumption that 





4.2.2.4. Fourier Transform Infrared Spectroscopy (FTIR).  
euterium oxide exchanged samples  were prepared as reported previously2 
.  Approximately 0.5 mg of solid 
0 mg/ml in D2O solution) was 










employing the lyophilization cycle described above
sample was used in diffuse reflectance (DRIFT) infrared measurement.13 A diffuse 
reflectance accessory Graseby Specac Minidiff™ PN 4500 (Graseby Specac Inc., 
Faifield) was utilized in all measurements. Infrared spectra were recorded with a 
Nicolet Magna 560 ESP spectrometer (Nicolet Instrument, Madison, WI). For each 
spectrum, a 256-scan interferogram was collected in single beam mode with 4 cm-1 
resolution. For the aqueous samples, native hGH (2
p
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CT). The exchange into D2O was performed by lyophilization of the protein and 
suspension in D2O.  
he analysis of the spectr ted moisture content is 
escribed in detail elsewhere.2  Briefly, each spectrum was corrected for scattering 
lution and was utilized to calculate the 
redicted moisture content. The ass e moisture content of a sample 
ith a relative carboxylate band area between 0 and 1 would fall between 0 and 12% 
oisture was utilized. 
rotein 
re
T a and calculation of the predic
d
with Kubelka-Munk correction utilizing GRAMS/AI (7.0) software (Thermo 
Galactic). The amide I second derivative spectrum was area normalized. The area of 
the carboxylate peak at 1580 cm-1 was expressed as the fraction of the carboxylate 
band area measured for the native protein in so




4.2.3. Conformational Characterization of Freeze-Dried P
Infrared spectra were recorded using a Nicolet Magna 560 ESP spectrometer (Nicolet 
Instrument, Madison, WI) in a DRIFT mode.13 A diffuse reflectance accessory 
Graseby Specac Minidiff™ PN 4500 (Graseby Specac Inc., Faifield) was utilized in 
the measurement of a solid sample. For each spectrum, a 256-scan interferogram was 
collected in the single beam mode with 4 cm-1 resolution. The analysis of spectra and 
the calculation of the correlation coefficient is described in detail elsewhere.14-17 
Briefly, the amide I region of each spectrum was corrected for scattering with a 
Kubelka-Munk correction and the area normalized second derivative spectra were 





where xi is the intensity of the spectrum for solid sample and yi is the intensity of the 
spectrum of protein in solution at a wavenumber (i). 
An aqueous sample (20 mg/ml in H2O solution) was placed onto a ZnSe attenuated 
total reflectance (ATR) crystal (Spectra-Tech, Shelton, CT) and the spectra were 
recorded as described above. 
 
4.2.4. Structural Mobility Measurements 
The Tg values (onsets of the thermal transition) were measured with the Q100-DSC 
A instruments Inc., New Castle, DE) at heating rates of 2, 5, 10, 15 and 20°C/min. 




∑ xi2 ∑ yi2√
(T
Indium was used to calibrate the temperature and cell constant. 
temperature of three measurements was reported as the glass transition temperature. 
The slope of the glass transition temperature changes as a function of scanning rate 
was used to calculate a fragility factor (m), which was further utilized for calculation 
of the parameters D and T0. The parameters were utilized to estimate molecular 
relaxation time (τ) employing the Vogel–Tammann–Fulcher (VTF) equation.9
 
 τ = τ0exp( )DT0T – T0
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where τ0 (~10-14s) is the relaxation perature, D is a parameter 
lated to the fragility of material, and T0 is the temperature at which the relaxation 
me tends towards infinity. 
e reproducibility, 2 samples were assayed at each time 
oint. Deamidation of the hGH was monitored by reverse phase (RP) - HPLC using a 
zu LC instrument (Kyoto, Japan) was 
 rate of 
 ml/min was utilized for size exclusion separation and UV detection at 220 nm. 
ormation of hGH insoluble aggr easuring the differences in 
concentration before and after filtration through a 0.22µm filter3 and the data were 
fitted to “square root of time” kinetics.19,21  




4.2.5. Stability Studies 
Lyophilized samples were placed in an incubator (Precision scientific, Chicago, IL) at 
50 ± 1°C for 7 months. At different storage times, the samples were reconstituted 
with 1 ml of water. To assur
p
method developed previously.18 Shimad
equipped with a LC6A pump, SPD-6A UV detector, SCL-613 system controller and 
SIL-10AXL auto-injector.  A Vydac C4 column with a mobile phase of 29% n-
propanol and 71% 0.005 M Tris buffer at pH 7.5 was utilized for isocratic separation 
with UV detection at 220 nm. The stability data were fitted to a first order rate 
equation to obtain the rate constants.19  Formation of hGH soluble aggregates was 
monitored by SEC-HPLC as reported earlier10,20 and an equation describing “square 
root of time” kinetics19,21 was used to fit the data. A TSK G3000SW column (Toyo 
Soda) with mobile phase containing 0.025 M ammonium bicarbonate at a flow
1
F egates was studied by m
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4.2.6. Studies of Solution Protein Formulations Before Lyophilization 
 
4.2.6.1. High-Resolution UV Absorbance Spectroscopy.  
ne and in solution containing sucrose or trehalose was studied Aggregation of hGH alo
using an Agilent 8453 UV-visible spectrophotometer by monitoring optical density at 
350 nm (OD 350 nm) every 2.5°C over the temperature range of 10 to 85°C. A 5 min 
incubation period (sufficient for equilibrium to be reached) was employed at each 
temperature point. 
 
4.2.6.2. Dynamic Light Scattering (DLS). 
 The mean hydrodynamic diameter of the hGH in solution with and without excipient 
was analyzed with a dynamic light scattering instrument (Brookhaven Instrument 
Corp., Holtzille, NY). The instrument was equipped with a 50 mW diode-pumped 
laser (λ = 532 nm) and the scattered light was monitored at 90° to the incident beam. 
Autocorrelation functions were generated using a digital auto-correlator (BI-
9000AT). The hydrodynamic diameter was calculated from the diffusion coefficient 
by the Stokes-Einstein equation using the method of cumulants (lognormal number 
based).  
 
4.2.6.3. Differential Scanning Calorimetry.  
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Solution DSC was performed using a MicroCal VP-DSC with autosampler 
alone and in 
e presence of excipient were obtained from 10-90°C using a scan rate of 60°C/hr. 
efore beginning each scan. 
.3.1. Extent of protein-excipient interactions 
hGH and sucrose or trehalose was studied 
nd sugar.  
ISC studies showed that both hGH/sucrose and hGH/trehalose mixtures had 
igure 4.2). The dissolution of the 
hGH/excipient colyophilized mixture was less exothermic than the physical mixture 
(MicroCal, LLC; Northampton, MA). Thermograms of hGH (1 mg/ml) 
th
The filled cells were equilibrated for 15 min at 10°C b
Thermograms of the buffer alone were subtracted from each protein scan prior to 
analysis. 
 
4.3. Results and disscussion 
 
4
The extent of interaction between 
with ISC, DSC, WSA and FTIR measurements. Comparison of the theoretical and 
measured Tg values for the hGH/sugar formulations is shown in Figure 4.1. The 
measured Tg (371.5 ± 0.4 K for hGH/sucrose and 400.1 ± 0.4 K for hGH/trehalose) 
was significantly lower than the theoretical value (398 K for GH/sucrose and 422 K 
for GH/trehalose) in both the formulations. The larger difference between the 
theoretical and observed Tg in the case of hGH/sucrose formulation suggests that this 
mixture is more homogeneous and has a greater extent of interaction between the 
protein a
exothermic enthalpies of dissolution (F
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in both the formulations. The enthalpy of interaction (the difference of the enthalpy of 
dissolution between the colyophilized and physical mixtures) was almost twice as 
much in the case of hGH/sucrose (2.1 ± 0.1 kcal/g) compared to hGH/trehalose (1.3 ± 
0.1 kcal/g) formulation. This suggests that both sugar containing formulations had 
detectable levels of intermolecular interactions and that the hGH/sucrose formulation 
had a greater extent of such interactions in agreement with the DSC results. 
 The WSA based interaction parameter was also much higher in case of 
 trehalose containing formulation over the range of 10-
0% RH (Figure 4.3). Surprisingly, the moisture content based on the FTIR 
oisture content in both 
formula
mogeneous mixture and/or more favorable spatial arrangement of 
the H-b
hGH/sucrose compared to the
4
carboxylate band area was lower than the actual m
tions (Table 4.1). Thus, the FTIR based approach does not appear to be 
appropriate to measure the extent of the protein-excipient interactions in the case 
studied here.  
DSC, ISC and WSA based evaluations of the extent of protein-excipient 
interactions demonstrate that hGH formulations containing sucrose and trehalose 
possess detectable extents of interaction between sugar and protein. In addition, the 
hGH/sucrose formulation displays a greater extent of interactions compared to the 
hGH/trehalose mixture. The latter observation probably is related to the presence of a 
more chemically-ho
onding groups in case of sucrose. It has been suggested that partial phase 




4.3.2. Structural Mobility Measurements 
The slope from the dependence of the glass transition temperature on scanning 
rate was utilized to calculate initial relaxation times employing the Vogel–Tammann–
Fulcher equation.9 The initial relaxation time at 50°C was 4x1010s for hGH/trehalose 
and 6.4x105s for the hGH/sucrose formulation.  The much smaller relaxation time 
seen in
lization of hGH in the absence of sugars led to a significant 
perturb
 the sucrose formulation suggests a correspondingly rapid structural relaxation. 
Thus, the hGH/trehalose seems to possess a more rigid matrix and slower molecular 
mobility at 50°C. Similar observations that trehalose/protein mixtures display slower 
structural relaxation than sucrose/protein formulations has been reported previously.23  
 
4.3.3. Conformational Characterization of Freeze-Dried Protein 
Lyophi
ation of its secondary structure as shown in Figure 4.4. The correlation 
coefficient describes structural differences between the native protein in solution and 
the protein in the lyophilized state. The correlation coefficient close to 1.00 
corresponds to a protein with unperturbed by lyophilization secondary structure. The 
correlation coefficient for the lyophilized sugarless hGH was 0.77, whereas addition 
of an excipient (sucrose or trehalose) led to preservation of secondary structure and a 
high correlation coefficient (~0.98). Both the hGH/sucrose and hGH/trehalose 
formulations had similar correlation coefficients.  
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4.3.4. Stability Studies 
ehalose formulations had similar rates of 
deamid
leads to the formation of a more homogeneous mixture with a decreased extent of 
as much slower in 
the hGH
any differences in behavior (Table 
4.4). The thermally induced aggregation of hGH had the same onset temperature in 
Both the hGH/sucrose and hGH/tr
ation and insoluble aggregate formation (Figures 4.5 and 4.6, and Table 4.2). 
It is important to note, however, that the stability of the lyophilized hGH in the 
absence of any lyo-protectants was significantly decreased. The hGH/sucrose 
displayed significantly less insoluble aggregates immediately after lyophilization 
(Figure 4.7, Tables 4.2 and 4.3). This suggests that sucrose serves as an efficient lyo- 
and cryo- protectant against lyophilization induced stresses that lead to formation of 
the insoluble protein.  Moreover, the greater extent of protein-excipient interactions 
seen in hGH/sucrose formulation supports the hypothesis that the presence of sucrose 
aggregation. In contrast, the rate of insoluble aggregate formation w
/trehalose formulation (Table 4.2). This decreased rate of aggregation may be 
related to the slower structural relaxation (molecular mobility) of the trehalose 
containing matrix.  
 
4.3.5. Studies of Protein Formulations before Lyophilization 
hGH was also characterized in solution with and without trehalose or sucrose. 
The mean hydrodynamic diameter of hGH (~5 nm) remained unchanged despite the 
presence or absence of the sugars. Thermally induced unfolding of hGH was 
monitored with solution DSC and did not reveal 
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all formulations. The midpoint temperature of thermally induced aggregation, 
howeve
s can be correlated with the greater extent of the hGH-excipient 
interactions and the presence of a more homogeneous matrix.  In contrast, the higher 
 may be related to the 
greater
r, was delayed by 2-6°C in the presence of the sugars. Sucrose was more 
effective in delaying the midpoint temperature of the observed aggregation. The 
tendency of sucrose to alter the pattern of the thermally induced aggregation of hGH 
may be related to its ability to serve as a potent cryo- and lyo- protectant as seen in 
reduced insoluble aggregate formation upon lyophilization. 
 
4.4. Summary and conclusions 
hGH formulations containing sucrose demonstrated greater protein-excipient 
interactions and faster initial relaxation times than formulations containing trehalose. 
Although both formulations had similar rates of deamidation and soluble aggregate 
formation, the extent and rate of insoluble aggregate formation was different. The 
hGH/sucrose formulation demonstrated a higher rate and lower extent of insoluble 
aggregate formation. The decreased amount of higher order aggregate seen in the 
sucrose formulation
rate of insoluble aggregate formation in the sucrose formulation
 molecular mobility of its amorphous matrix. Additionally, the characteristics 
of the protein in the presence of the sugar(s) may be related to the cryo- and lyo- 
protective properties of the excipient(s). Relationships between the extent of protein-
excipient interactions, structural relaxation of the matrix and protein stability are 
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  Tg values of colyophilized a) hGH/sucrose, and b) hGH/trehalose 
rmulations as a function of composition. Measured Tg values are represented as 
mbols and the prediction by Gordon-Taylor equation is represented by the dotted 





































igure 4.2.  Enthalpy of dissolution for colyophilized (dark bars) and physical (white 





















































        





























































































Figure 4.4.  Second derivative amide I FTIR spectra of native hGH in solution (1), 



























































hGH alone (▲ and dotted line), hGH with sucrose (♦ and solid black line) and hGH 















































Figure 4.6.  The kinetics of soluble aggregate formation in lyophilized formulations 
containing hGH alone (▲and dotted line), hGH with sucrose (♦ and solid black line) 






















































Figure 4.7.  The kinetics of insoluble aggregate formation in lyophilized mixtures 
containing hGH with sucrose (♦ and solid black line) and hGH with trehalose (■ and 




Table 4.1. Predicted and actual moisture content for hGH/excipient formulations. The 
rediction of moisture content was based on the area of the carboxilate band at 1580 
m-1 from FTIR measurements. 













hGH/sucrose 1.76 ± 0.14 0.00455 0.095 1.14 





































h 0.0GH/sucrose 0.019 ± 0.01 0.4 ± 0.2 2.38 ± 1 
h 0   ± 0.06 GH/trehalose .021 ± 0.01 0.7 ± 0.1 1.97





Table 4.3. Percent insoluble aggregate formed immediately after lyophilization and 





% insoluble aggregate 
lati
ks 





initial after 28 wee
hGH/sucrose 12.0 ± 0.2 
.0 ± 0.2 15.0 ± 0.2 
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Table 4.4. Midpoint transition temperature (Tm) for hGH in solutions with and 
without sugar. The Tm was monitored with solution DSC. The midpoint of the 
mperature of thermal aggregation was monitored by the OD at 350 nm. 
 Tm 
Formulation DSC t 350 nm 
79.0 ± 0.1 










hGH 74.5 ± 0.6 
















5.1. Solution protein formulations 
.1.1. Summary and conclusions 
Chapters 2 and 3 describe studies directed towards physical characterization 
of Clostridium difficile (C. difficile) toxins, understanding the effects of formaldehyde 
crosslinking on the toxoids’ thermal stability as well as preformulation studies of free 
and bound (to adjuvant) toxoids. The C. difficile toxins are responsible for C. difficile-
associated disease (CDAD), whi prevented by vaccination with 
formaldehyde crosslinked (inactivated) toxoids A and B.1-5, 6-9 Since the A and B 
toxoids are current candidates for vaccine development, a better understanding of 
toxin and toxoid structure as a function of pH and temperature as well as 
identification of stabilizing compounds is potentially of a significant interest. 
Our stepwise approach permitted the rational design of a study which 
generated critical information for eventual vaccine formulation. As described in 
Chapter 2, C. difficile toxins were characterized at pH 5-8 over the temperature range 
of 10-85°C. Structural changes and aggregation behavior were monitored with 
circular dichroism, intrinsic and extrinsic (ANS) fluorescence spectroscopy, turbidity 
measurements, high resolution UV absorbance spectroscopy and dynamic light 
scattering. The two toxins had similar secondary structure displaying a combination 
of helical, ß-sheet and unordered character.  The absence of information on the 




ch might be 
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observed large overall helical content of the toxins’ appears to arise from 
ontributions from a combination of the amino-terminal domain and undefined 
 seen that the A and B toxins are partially unfolded 





middle parts of the proteins. It was
a
tions are consistent with previously reported pH-induced conformational 
changes of toxin B in early endosomes and proposed mechanisms of toxins entry into 
cells.12-14
The A and B Clostrodial toxins displayed some variation in properties and 
quite distinct thermal behavior. Toxin A possesses an apparent hydrodynamic 
diameter twice that of toxin B and tends to precipitate upon heating at all pH values. 
In contrast, toxin B only precipitated at pH 5-6 and formed soluble aggregates at pH 
6.5-7.5. It was proposed that the observed dissimilarities between the toxins could be 
related to differences in their structure (specifically, the carboxy-terminal d
echanisms of action (enterotoxicity in animals) and their enzymatic activity 
(velocity and extent)15.  
The combined results were mathematically analyzed to produce eigenvectors 
and eigenvalues which were visualized  in empirical phase diagrams as described 
previously.16 This showed that upon heating, toxin A at all pH values partially 
unfolded at ~45°C and formed insoluble aggregates at ~50°C. Toxin B partially 
unfolded at ~40°C, and upon heating to ~50°C precipitated at pH 5.0-6.0 and formed 
soluble aggregates at pH 6.5-7.5. The thermal stability of the toxins was pH 
dependent with the proteins more thermally stable at higher pH. 
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Similar studies of the formaldehyde crosslinked A and B toxoids revealed 
enhanced thermal stability compared to their corresponding toxins, in which 
secondary and tertiary structure changes as well as aggregation were delayed by about 
10°C. The toxoid A displayed the following structural states: 1) partially unfolded at 
pH 5.5; 2) folded in the pH range 6-8; 3) a transition in form between 50 and 65°C 
and 4)  the presence of insoluble aggregates above 50 – 65°C. The corresponding 
phase diagram for toxoid B provides the related structural description: 1) partially 
unfolde
s of intramolecular crosslinking on a variety of toxins with 
formald
gation of the toxoids 
d at pH 5.0; 2) folded in the pH range 5.5-7.5; 3) transition at 50-65°C; 4) 
insoluble aggregate appearance at pH 5.0 and 5.5 and at temperatures above 55-60°C; 
and 5) soluble aggregate formation over the pH range 6-7.5 at temperatures above 
60°C.   
 These studies clearly demonstrated the stabilizing effect of formaldehyde 
crosslinking on the thermal stability of their corresponding toxoids. The effect of the 
formaldehyde crosslinking observed in our studies is consistent with previously 
reported favorable effect
ehyde.17-20
Further studies with the goal of enhancing the physical stability of the two 
Clostridium difficile toxoids are described in Chapter 3. Screening for stabilizing 
compounds was performed by studying effect of 30 GRAS compounds at various 
concentrations and in several combinations on the behavior of the proteins. The 
screening was conducted in two parts. First, a high-throughput aggregation assay was 
used to screen for compounds which delayed or prevented aggre
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under s
by the solutes. The possibility that the toxoids are partially unfolded upon 
binding
cking of the protein/protein interaction that are responsible for 
protein
tress conditions (pH 5-5.5 and 55°C). It was observed that 20% trehalose, 20% 
sucrose, 10% sorbitol, 10% dextrose and 20% glycerol efficiently inhibited 
aggregation of both of the toxoids. In the second part of the screening, these excipient 
and two surfactants (0.05% or 0.1% tween 80 and 0.1% pluronic F-68) were further 
studied for their ability to stabilize the protein’s secondary and tertiary structure at pH 
6.5. Monitoring CD signal changes upon heating revealed that some disaccharides 
(20% sucrose and/or 20% trehalose) produced an earlier onset of secondary structure 
change in both the toxoids. The rest of the excipients delayed the thermal transition 
by ~2°C. The early onset of the toxoids’ secondary structure change in the presence 
of trehalose and/or sucrose was explained by stabilization of partially unfolded 
state(s) 
 to their C-terminal carbohydrate recognition sequence repeats by the 
polysaccharides21 was not ruled out. It was proposed that the excipients do not 
strongly stabilize the structure of the toxoids by the well described  preferential 
exclusion mechanism22,23 but rather inhibit their aggregation by other mechanisms, 
such as direct blo
 association. 
The effect of a combination of the more active agents (sorbitol, dextrose and 
tween 80) on secondary structure was characterized by monitoring the toxoid’s 
thermal transitions with CD and aggregation with OD 350 nm measurements. The 
concentration of the excipients had an approximately linear effect on the temperature 
of the thermal transitions. The combination of 10% dextrose and 10% sorbitol in the 
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presence or absence of 0.05% tween 80 delayed the midpoint of the thermal transition 
of both of the toxoids to a significant extent (~4°C for toxoid A and ~10°C for toxoid 
B), due to either a synergistic effect and/or the higher total concentration of the 
stabilizing compounds. These studies suggested that this particular combination of 
potential vaccine excipients stabilizes the toxoid’s structure by both a preferential 
hydration mechanism and direct inhibition of protein association. The use of such 
stabilizing compounds could potentially increase the physical stability of the toxoids 
during storage. 
Adjuvant binding isotherms revealed that the toxoids efficiently bind to 
Alhydrogel® at low concentrations and that their binding is saturated at higher protein 
concentration (~1 mg/ml). Desorption studies in the presence of 2 M NaCl indicated 
that the interaction of toxoids with Alhydrogel® was not solely electrostatic as is often 
observed in protein/Aluminum hydroxide interactions24-26. Interestingly, upon binding 
to Alhydrogel®, toxoid A manifests no detectable change in its thermal stability. In 
contrast, adjuvant bound toxoid B demonstrates a decrease of its Tm by ~1.4°C.  The 
fraction of Alhydrogel® bound toxoid was reduced in the presence of most of such 
compunds suggesting that such compunds partially interfere with toxoid binding to 
Alhydrogel®. Finally, DSC studies of Alhydrogel® bound toxoids in the presence of 
selected excipients identified conditions (10% sorbitol, 10% dextrose with 0.05% or 
0.1% tween 80) that produced improved physical stability of the adjuvant bound 
proteins.  
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This study of C.difficile toxins A and B demonstrated both similarities 
(secondary structure and low pH induced partial unfolding) and differences (stability 
and thermal behavior) between the two toxins. The superiority of the formaldehyde 
crosslinked toxoids’ thermal stability illustrates the power and utility of this approach 
for vaccine development. The systematic approach to stabilizer screening resulted in 
the identification of excipients which improved the thermal stability of both C. 
difficile toxoids. Studies of Alhydrogel® bound toxoids in the presence of selected 
excipients identified conditions that produced improved physical stability of the 
adjuvant bound proteins. This information concerning the toxoids physical behavior 
under a range of conditions (temperature, solute) should be useful in the design of 
pharmaceutical formulations of enhanced storage stability.  
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5.1.2. F
, concentration, solutes). 
Accelerated stability studies may result in the more rapid identification of conditions 
ultimately leading to appropriate protein stability during long term storage.  Although 
prediction of degradation rates may not be possible, such studies are expected to 
reveal the presence of relevant degradation pathways. This, in turn, will provide the 
information necessary to select appropriate assays. Final long term stability studies 
employing these assays are performed under the selected storage conditions (usually 
refrigerator temperature) over the desired storage period (1-3 years).27-29  
  Since the administration of both toxoids simultaneously is favored to trigger 
the appropriate immune responses, it is desired to formulate both the A and B toxoids 
in a single formulation.  A formulation containing two toxoids, however, may present 
a problem since it would be necessary to monitor the physical and chemical stability 
uture directions  
 
 To select appropriate conditions for the optimum storage of C. difficile 
vaccines, it is important to perform expanded preformulation/formulation studies of 
the toxoids. To this end accelerated and long term storage stability studies are 
required. Such accelerated stability studies are usually performed at 3-4 different 
temperatures conditions (in this case 4, 15, 25, 35 and 40°C might be appropriate) and 
analyzed for presence of degradation products and biological activity at various time 
points. Even though Arrhenius behavior is often not observed in macromolecules, the 
accelerated stability studies are usually employed to provide critical information 
about protein behavior under different conditions (e.g. pH
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of the individual protein during the stability studies. To permit the study of the 
dividual protein in such a binary mixture, it would be necessary to utilize advanced 
ethod
in
m ologies of separation and analysis that are beyond the scope of this discussion.  
 Additionally, to increase level of toxoid-induced immune responses, the 
proteins must almost certainly be administered bound to aluminum salt (or some 
other) adjuvants. Thus, further optimization in terms of toxoid/adjuvant interactions 
will be necessary.  Furthermore, studies of formulation containing adjuvant adsorbed 
toxoids will require a desorption step prior to analysis that must be developed. 
Alternatively, development of analytical technique capable of studying the stability of 
surface adsorbed protein would be necessary. 
 Formulation of vaccines is an extremely complex process which requires a 
thorough understanding of an antigen’s properties, stability and activity over a wide 
range of conditions. Clearly, there is room for further improvements in this process.   
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5.2. Solid protein formulations 
 
5.2.1. Summary and conclusions of chapter 4 
  
 To better understand the influence of the extent of protein/excipient 
interactions and molecular relaxation of the accompanying matrix on chemical (e.g. 
deamidation, oxidation, etc.) and physical (e.g. conformational integrity, formation 
of soluble and insoluble aggregates, etc.) protein stability, a model system containing 
human growth hormone (hGH) in the presence of two carbohydrates (sucrose and 
trehalose) was studied. Immediately after lyophilization, the extent of interactions 
mploying DSC). This was used to calculate initial relaxation times employing the 
Vogel–Tammann–Fulcher (VTF) equation.36 Additionally, hGH with and without 
sucrose and trehalose was characterized by a variety of techniques in solution to see 
to what extent solution properties might be predictive of the protein in the 
lyophilized solid. The physical and chemical stability of lyophilized hGH 
formulations during storage at 50°C for seven month was monitored by RP-HPLC, 
SEC-HPLC and UV. The hGH formulations containing sucrose demonstrated greater 
protein/excipient interactions and faster initial relaxation times compared to trehalose 
formulations. Although both formulations had similar chemical stability (rate of 
between hGH and the sugars was measured with a number of different techniques 
including ISC, DSC, WSA and FTIR.30-35 The fragility of the amorphous matrix was 
determined from the dependence of its glass transition temperature on scanning rate 
(e
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deamidation), their physical stabilities (degree of aggregation) were different. The 
GH/sucrose formulation manifested a higher rate and lower extent of insoluble 
t of aggregation in the sucrose 
d be correlated with a greater extent of protein/excipient interaction 
h
aggregate formation. The decreased amoun
formulations coul
and the presence of a more homogeneous mixture.  In contrast, the higher rate of 
aggregation seen in the sucrose formulation could be directly correlated with the 
higher molecular mobility of the matrix. Additionally, characteristics of the protein 
in the presence of sugar(s) may be related to the cryo- and lyo- protective properties 
of the excipient(s). Relationships between the extent of protein/excipient 
interactions, structural relaxation of the matrix and   protein stability are evident and 
can potentially serve as a basis for the development of more stable lyophilized 
formulations.  
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5.2.2. Future directions 
 
Development of a solid protein formulation requires optimization of 
lyophilization process and consideration of the properties of the lyophilized solid. 
Optimization of the lyophilization process usually involves adjustment of freezing, 
primary drying and secondary drying steps to result in a lyocake with the desired 
properties. The properties of the lyocake such as residual moisture content, 
preservation of protein secondary structure, structural relaxation of matrix, and 
homogeneity of protein/excipient mixtures are usually evaluated. Numerous studies 
tried to correlate the properties of the lyophilized formulations with the short and long 
term stability of proteins. Unfortunately, most of the published results can be related 
only to the particular system studied and each protein formulation requires a different 
approach due to the unique characteristics of the individual protein.37-39  
Recent studies showed that the preservation of protein native structure in solid 
formulations is directly related to long term stability of some proteins. In contrast, the 
molecular mobility of amorphous matrix (long range motions) poorly correlates with 
the stability. It was proposed that the specific interaction between stabilizer and 
protein might be responsible for the preservation of protein native structure and that 
short range motions of the amorphous matrix might influence the protein stability.40,41
The results of the study of the model system containing hGH and two 
isomeric sugars supported the importance of the protein/excipient interactions and the 
homogeneity of the amorphous mixture in the stability of the protein formulation 
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during accelerated stability studies. The clear correlation of protein stability with the 





ith hGH may not necessarily be seen in other systems. Therefore, a study of a 
diverse library of proteins and excipients is required to test the consistency of our 
observations. Moreover, it would be of a great interest to study such formulations 
with a greater variety of isomeric stabilizer pairs at different ratios at the conditions of 
the accelerated and long term storage. A better understanding of the role and 
influence of each excipient in a mixture could potentially result in lyophilized 
formulations with significantly improved stability.  
Additionally, evaluation of protein tertiary structure in solid formulation, 
monitoring of protein motions as well as short range mobility of an amorphous matrix 
in general and more in depth understanding of the specific interactions between 
protein and excipient will lead to a better understanding of the amorph
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